Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial

Radhika Nair,1,2 Nishita Singh,2,3 Mahesh Kate,4,1 Negar Asdagh,4 Robert Sarmiento,1 Fouzi Bala,5,6 Shelagh B Coutts,3 MacKenzie Horn,6,3 Alexandre Y Poppe,7 Heather Williams,8 Ayooja Ademola,9 Ibrahim Alhabli,5 Faysal Benali,5 Houman Khosravani,10 Gary Hunter,11 Aleksandr Tkach,12 Herbert Alejandro Manosalva Alzate,13 Aleksandra Pikula,14 Thalia Field,15 Anurag Trivedi,16 Dar Dowlatshahi,17 Luciana Cataneo,18 Ashfaq Shuaib,1,1,a Andrew Demchuk,3 Tolulope Sajobi,3 Mohammed A Almekhlafi,3 Richard H Swartz,16 Bijoy Menon,3 Brian H Buck,1


ABSTRACT
Background In ischaemic stroke, minor deficits (National Institutes of Health Stroke Scale (NIHSS) ≤5) at presentation are common but often progress, leaving patients with significant disability. We compared the efficacy and safety of intravenous thrombolysis with tenecteplase versus alteplase in patients who had a minor stroke enrolled in the Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke (AcT) trial.

Methods The AcT trial included individuals with ischaemic stroke, aged >18 years, who were eligible for standard-of-care intravenous thrombolysis. Participants were randomly assigned 1:1 to intravenous tenecteplase (0.25 mg/kg) or alteplase (0.9 mg/kg). Patients with minor deficits pre-thrombolysis were included in this post-hoc exploratory analysis. The primary efficacy outcome was the proportion of patients with a modified Rankin Score (mRS) of 0–1 at 90–120 days. Safety outcomes included mortality and symptomatic intracranial haemorrhage (sICH).

Results Of the 378 patients enrolled in AcT with an NIHSS of ≤5, the median age was 71 years, 39.7% were women; 194 (51.3%) received tenecteplase and 184 (48.7%) alteplase. The primary outcome (mRS score 0–1) occurred in 100 participants (51.8%) in the tenecteplase group and 86 (47.5%) in the alteplase group (adjusted risk ratio (RR) 1.14 (95% CI 0.92 to 1.40)). There were no significant differences in the rates of sICH (2.9% in tenecteplase vs 3.3% in alteplase group, unadjusted RR 0.79 (0.24 to 2.54) and death within 90 days (5.5% in tenecteplase vs 11% in alteplase group, adjusted HR 0.99 (95% CI 0.96 to 1.02).

Conclusion In this post-hoc analysis of patients with minor stroke enrolled in the AcT trial, safety and efficacy outcomes with tenecteplase 0.25 mg/kg were not different from alteplase 0.9 mg/kg.

INTRODUCTION
Approximately one-half of patients with acute ischaemic stroke present with minor deficits defined as a National Institutes of Health Stroke Scale (NIHSS) score of ≤5.5 While low NIHSS is a common reason for thrombolysis exclusion,3 deficits that are initially minor can involve functionally important domains such as vision and language4 and progress, leaving nearly one-third of patients disabled or dead at 90 days.5,6 Evidence for the benefit of intravenous thrombolysis with alteplase within 4.5 hours in minor stroke comes from trials that largely limited enrolment to patients presenting with disabling deficits.7,8 Approximately 10% of the 6765 patients enrolled in the nine randomised
trials comparing alteplase with placebo had a baseline NIHSS of 0–4 with all trials except IST-3 excluding those with non-disabling deficits. A meta-analysis of individual patient data from these nine trials showed that the benefit of alteplase was similar (relative OR 1.48 (1.07 to 2.06)) in patients with minor deficits compared with more severe strokes. In contrast, in minor strokes with non-disabling deficits, a benefit of intravenous thrombolysis over antiplatelet agents has not been shown. The PRISMS (Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits) trial compared intravenous alteplase with aspirin in patients with minor non-disabling deficits. The study was terminated early by the sponsor due to slow patient enrolment. The study showed no differences between groups in excellent functional outcomes at 90 days (modified Rankin Scale (mRS) score 0 or 1); however, there was a significant increase in symptomatic intracerebral haemorrhage (sICH) in the alteplase group. More recently, the ARAMIS trial compared dual antiplatelet therapy (DAPT) with 0.9 mg/kg of alteplase in minor non-disabling acute stroke and showed that DAPT was non-inferior to alteplase for functional outcomes. Based on these trials, current guidelines recommend limiting intravenous thrombolysis with alteplase in patients with acute minor stroke to those with disabling deficits.

Recent randomised trials comparing thrombolysis with alteplase 0.9 mg/kg with tenecteplase 0.25 mg/kg, in patients with acute ischaemic stroke including those with minor deficits, have demonstrated the non-inferiority of tenecteplase. As a result, there has been a transition in many stroke systems from alteplase to tenecteplase as the standard of care for acute thrombolysis. However, there are limited data comparing the clinical outcomes and safety of tenecteplase at a dose of 0.25 mg/kg with standard-dose alteplase in unselected minor stroke. In this post-hoc analysis of the Alteplase Compared to Tenecteplase (AcT) randomised controlled trial, we aimed to evaluate the effectiveness and safety of tenecteplase compared with alteplase in the subgroup of patients, presenting with an NIHSS of 5 or less, eligible for standard-of-care thrombolysis based on current Canadian guidelines.

**METHODS**

**Study design and setting**

The AcT trial (ClinicalTrials.gov NCT03889249) was an investigator-initiated, pragmatic, multicentre, parallel-group, open-label, registry-linked, randomised control non-inferiority trial that compared the effectiveness of tenecteplase versus alteplase for acute ischaemic stroke. The trial protocol (online supplemental file 1) and main results have been reported elsewhere. Briefly, patients were recruited at 22 stroke centres across Canada between 10 December 2019 and 25 January 2022. Included patients were those presenting within 4.5 hours of symptom onset with a diagnosis of acute ischaemic stroke and meeting eligibility for thrombolysis with intravenous alteplase as per the Canadian Stroke Best Practices Guidelines. For minor stroke, the Canadian guidelines suggest thrombolysis only in those with disabling deficits (ie, significantly impacting functioning without qualification of specific deficits). The detailed inclusion and exclusion criteria along with the original study protocol are published elsewhere. Included patients were randomised 1:1 to receive either tenecteplase at a dose of 0.25 mg/kg or alteplase 0.9 mg/kg (10% bolus followed by infusion over 60 min). The primary outcome was the proportion of patients with an mRS score of 0 or 1 at 90–120 days after randomisation.

**Study outcome measures**

The present analysis was a post-hoc analysis of efficacy and safety outcomes of all patients enrolled in AcT with an NIHSS of 5 or less at presentation in the tenecteplase and the alteplase group. All patients randomised in the trial were included in this analysis (intention-to-treat population). The primary efficacy outcome was the proportion of patients with an mRS score of 0 or 1 at 90–120 days after randomisation. Secondary outcome measures of efficacy consisted of mRS score 0–2 at 90–120 days, ordinal shift of mRS score at 90–120 days, EQ-5D Visual Analogue Scale (EQ-5D VAS), return to baseline function and length of hospital stay. The safety outcome measures included death within 90–120 days, sICH at 24 hours (graded using the Heidelberg classification), systemic haemorrhage requiring blood transfusion, orolingual angioedema and other serious adverse events and imaging-identified intracranial haemorrhage.

**Statistical analysis**

Participants’ characteristics were described as mean±SD for normally distributed data, median (IQR) for non-normally distributed data and frequency (proportions) for discrete variables. Differences in primary, secondary and safety outcomes in patients receiving tenecteplase versus alteplase in this population are reported using unadjusted risk ratios (RRs) along with their 95% CIs. All unadjusted analyses were supported by adjusted analysis using generalised mixed-effects regression with a quasi-Poisson link function that adjusted for age, sex and occlusion site as fixed-effects variables, with the participating site as the random-effects variable to account for clustering of data within sites. The association between treatment and mortality was further examined using Kaplan-Meier survival curves with mortality compared between tenecteplase and alteplase-treated patients using a Cox proportional hazards regression adjusted for age, sex and occlusion site. The heterogeneity of treatment effect was assessed across the prespecified subgroups of age (<80 vs ≥80 years), sex (male vs female), Alberta Stroke Program Early CT Score (5–7 vs 8–10), occlusion site (M1-middle cerebral artery (MCA), M2-MCA, distal occlusion and vertebrobasilar), large vessel occlusion (present vs absent).
and carotid tandem occlusion (present vs absent). A two-sided p<0.05 was considered statistically significant. The analysis plan was formulated after the completion of the analysis for the main trial. There is a potential for type 1 error due to multiple statistical tests without adjustment of p values; therefore, all analyses should be considered exploratory. All analyses were conducted using Stata V.16.0 SE (StataCorp).

**RESULTS**

**Patient characteristics**

Between December 2019 and January 2022, 1600 patients were enrolled and randomised in the AcT trial, with 1577 participants included in the intention-to-treat analysis of the primary outcome (online supplemental figure 1). Of these 1577 patients, 378 (24.0%) patients presented with an NIHSS of 0–5 with 194 of 378 (51.3%) receiving tenecteplase and 184 of 378 (48.7%) alteplase. The baseline characteristics of included participants are listed in Table 1. Their median age was 72 (IQR: 62–83) years in the tenecteplase group and 71 (IQR: 59–81) years in the alteplase group; 75 of 194 (38.7%) in the tenecteplase group and 75 of 184 (40.8%) in the alteplase group were female. Of the 194 patients in the tenecteplase group, 112 (57.7%) had visible vessel occlusion, and distal occlusions were seen in 41 patients (22.4%) followed by M2-MCA segment occlusion in 17 (9.3%) patients. The most common sites of occlusion were distal occlusions (defined as either MCA (M3 and beyond), ACA (A2 and beyond) or PCA (P2 and beyond)) which were seen in 43 (22.3%) patients followed by M2 segment MCA seen in 42 (21.7%) patients. For the patients in the alteplase group, fewer patients (82 (44.6%)) had visible vessel occlusion, and distal occlusions were seen in 41 patients (22.4%) followed by M2-MCA segment occlusion in 17 (9.3%).

**Table 2** summarises the primary and secondary efficacy outcomes of patients who had a minor stroke categorised by allocation to tenecteplase versus alteplase. The primary efficacy outcome of mRS 0–1 at 90–120 days was achieved
<table>
<thead>
<tr>
<th>Primary and secondary outcomes at 90–120 days for study participants treated with tenecteplase versus alteplase</th>
<th>Tenecteplase (n=194)</th>
<th>Alteplase (n=184)</th>
<th>Unadjusted risk ratio (95% CI)</th>
<th>Adjusted risk ratio (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified Rankin Scale score 0–1 at 90–120 days, n (%)</td>
<td>100 (51.8)</td>
<td>86 (47.5)</td>
<td>1.09 (0.88 to 1.23)</td>
<td>1.14 (0.92 to 1.40)</td>
</tr>
<tr>
<td><strong>Secondary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified Rankin Scale score 0–2 at 90–120 days, n (%)</td>
<td>143 (74.1)</td>
<td>126 (69.6)</td>
<td>1.06 (0.93 to 1.20)</td>
<td>1.09 (0.94 to 1.26)</td>
</tr>
<tr>
<td>Modified Rankin Scale score at 90–120 days, median (IQR)</td>
<td>1 (0–3)</td>
<td>2 (1–3)</td>
<td>0.74 (0.52 to 1.07)</td>
<td>0.69 (0.47 to 1.00)†</td>
</tr>
<tr>
<td>EQ-5D VAS at 90–120 days, median (IQR)</td>
<td>75 (61–86)</td>
<td>75 (60–90)</td>
<td>0.62 (-3.50 to 4.77)</td>
<td>0.99 (0.97-1.02)‡</td>
</tr>
<tr>
<td>Return to baseline function, n (%)</td>
<td>80 (42.5)</td>
<td>61 (35.3)</td>
<td>1.20 (0.92 to 1.56)</td>
<td>1.20 (0.90 to 1.59)</td>
</tr>
<tr>
<td>Endovascular thrombectomy utilisation, n (%)</td>
<td>22 (11.3)</td>
<td>15 (8.1)</td>
<td>1.39 (0.74 to 2.59)</td>
<td>0.88 (0.53 to 1.47)</td>
</tr>
<tr>
<td>eTICI 2b/3 at first angiographic run, n (%)</td>
<td>8 (36.4)</td>
<td>1 (6.7)</td>
<td>5.45 (0.75 to 39.21)</td>
<td>6.68 (0.49 to 90.57)</td>
</tr>
<tr>
<td>eTICI 2b/3 at final angiographic run, n (%)</td>
<td>9 (60)</td>
<td>21 (95.4)</td>
<td>1.59 (1.04 to 2.42)</td>
<td>1.57 (0.58 to 4.25)</td>
</tr>
<tr>
<td>Length of hospital stay, median days (IQR)</td>
<td>4 (2–8)</td>
<td>4 (2–7)</td>
<td>-0.47 (-2.6 to 1.70)</td>
<td>0.86 (0.79 to 0.93)‡</td>
</tr>
</tbody>
</table>

Data are n (%), median (IQR), mean (SD) or effect estimate with 95% CI in parentheses.

*Adjusted for age, sex, occlusion location as fixed-effects variables and participating site as a random-effects variable.
†Common OR is the OR for a unit increase in the modified Rankin Scale score for tenecteplase versus alteplase.
‡Risk ratio using mixed-effects linear regression model adjusted for age, sex, occlusion location as fixed-effects variables and participating site as a random-effects variable.

eTICI, expanded treatment in cerebral infarction; VAS, Visual Analogue Scale.
in 100 (51.8%) patients in the tenecteplase group and 86 (47.5%) in the alteplase group (adjusted RR 1.14; 95% CI 0.92 to 1.40) (table 2). The direction of the effect favoured tenecteplase across the full range of mRS scores (figure 1). No heterogeneity of treatment effect on the primary outcome was observed across any of the clinically relevant subgroups (figure 2). Secondary efficacy outcomes including mRS score of 0–2 at 90–120 days were achieved in 143 (74.1%) in tenecteplase vs 126 (69.6%) in the alteplase group (adjusted RR 1.09; 95% CI 0.94 to 1.26), with a median (IQR) mRS of 1 (0–3) in tenecteplase vs 2 (1–3) in the alteplase group (adjusted RR 0.69; 95% CI 0.47 to 1.0) (table 2). Other efficacy outcomes, including EQ-5D VAS, return to baseline function, endovascular thrombectomy utilisation and length of hospital stay, are summarised in table 2.

Safety outcomes
The safety outcomes are shown in table 3. sICH occurred in five (2.6%) participants in tenecteplase versus six (3.3%) in the alteplase group (adjusted RR 0.79; CI 0.24 to 2.54). Two patients in the tenecteplase group and three patients in the alteplase group had parenchymal haematoma type 2, and six patients in tenecteplase and three patients in alteplase had parenchymal haematoma type 1 (haematoma occupying <30% of infarct with no substantial mass effect). Rates of haemorrhagic transformation graded using the Heidelberg classification are shown in online supplemental figure 2. There was a single patient with orolingual angioedema in each group and no patients with peripheral bleeding requiring blood transfusion.

Figure 1  Distribution of the modified Rankin Scale (mRS) scores at 90–120 days in the intention-to-treat population. mRS scores range from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability and 6 death.

Death within 90–120 days occurred in fewer patients in the tenecteplase group compared with the alteplase group (11 (5.7%) and 20 (11.0%), respectively (adjusted HR 0.99; CI 0.96 to 1.02)). The cause of death for study patients was not available. In addition, Kaplan-Meier curves show similar times to death in both treatment groups within 7 days (adjusted HR 0.98 (0.94 to 1.02)) as well as 90–120 days (adjusted HR 0.99 (0.96 to 1.02)) (online supplemental figure 3).

DISCUSSION
In this post-hoc analysis of patients with minor ischaemic stroke enrolled in the AcT trial, treatment with tenecteplase at a dose of 0.25 mg/kg resulted in similar rates of excellent functional outcome (mRS score of 0–1) at 90–120 days compared with alteplase at a dose of 0.9 mg/kg. No significant differences were observed between tenecteplase and alteplase across most safety outcomes. While there were numerically fewer deaths...
in patients administered tenecteplase, these differences were not evident in the adjusted analysis, with most deaths occurring beyond 7 days and, therefore, less likely to be causally related to thrombolysis.25

The study provides insights into the functional outcomes of patients who had a minor stroke treated with standard-of-care intravenous thrombolysis. The results are consistent with previous reports that the majority of patients who had a minor stroke have excellent functional outcomes at 90–120 days and low complication rates with thrombolysis.26 While not tracked, most patients in this substudy presumably had disabling deficits at presentation, given the inclusion requirement that patients should be eligible for thrombolysis according to standard-of-care indications in Canada.16 In the main AcT trial, 35.8% of patients achieved the primary outcome of mRS 0–1 at 90–120 days, while in comparison, 49.2% of the subgroup with minor stroke had an excellent functional outcome at 90–120 days. The results also highlight that the prognosis of minor stroke when disabling on presentation is not always benign. At 90–120 days, 27.2% of patients in our study had residual moderate-to-severe disability or had died (mRS 3–6). Other studies of unselected minor stroke have reported similar rates of severe disability or death ranging from 20% to 30%.12 In comparison, in trials such as ARAMIS, where enrolment was limited to non-disabling stroke, good outcomes (mRS 0–2) were seen in 95% of patients and were similar in the tenecteplase and dual antiplatelet arms.13 The differences in outcomes between trials in minor stroke presenting with versus without disability may in part reflect an increased likelihood for disabling minor strokes to harbour more proximal occlusions. Other factors, including vascular comorbidities and stroke aetiological differences in the Chinese population enrolled in ARAMIS, may also be important.

The present results align with the main AcT trial and prospective observational data22 supporting that routine thrombolysis of minor stroke based on current guidelines with tenecteplase results in similar clinical and safety outcomes to alteplase. The AcT trial demonstrated the non-inferiority of tenecteplase compared with alteplase for intravenous thrombolysis.17 The results of this substudy are qualitatively similar, with a non-significant higher proportion of patients who had a minor stroke treated with tenecteplase achieving excellent and/or good functional outcomes compared with alteplase (mRS (0–1) at 90–120 days (51.8% tenecteplase vs 47.5% alteplase); mRS of 0–2 (74.1% tenecteplase vs 69.9% alteplase)). Higher tenecteplase dosing does not seem to improve outcomes

---

**Figure 2** Forest plot of the adjusted risk ratios for mRS 0–1 at 90–120 days stratified by clinically relevant subgroups. Models were adjusted for age, sex and occlusion location as fixed-effects variables, and site as a random-effects variable. P values for interactions were not significant for all subgroups (p<0.05). There were no patients with intracranial internal carotid artery occlusions in the alteplase group. ASPECTS, Alberta Stroke Program Early CT score; LVO, large vessel occlusion; M1-MCA, first segment of the middle cerebral artery; M2-MCA, second segment of the middle cerebral artery; mRS, modified Rankin Scale.
in minor strokes relative to standard-dose alteplase. The NOR-TEST trial compared tenecteplase at a dose of 0.4 mg/kg with 0.9 mg/kg alteplase. While not specifically a minor stroke trial, the included patients in NOR-TEST had a median NIHSS of 4, with >70% of patients having an NIHSS of <7. The NOR-TEST trial did not show that tenecteplase at this higher dose was superior to alteplase, with 64% of patients having an mRS 0–1 at 3 months in the tenecteplase group and 3.2% in the alteplase group.

This study also adds data regarding the safety of tenecteplase 0.25 mg/kg in patients presenting with minor deficits. A total of 2.6% of patients in the tenecteplase group vs 3.3% in the alteplase group (RR 0.79 (0.24 to 2.54)) had sICH at 24 hours. In comparison, in the main AcT trial, sICH at 24 hours was seen in 3.4% of patients in the tenecteplase group and 3.2% in the alteplase group overall. A similar rate of sICH was seen in the PRISMS trial, which included patients who had a minor stroke (NIHSS ≤5) with non-disabling deficits, and reported sICH in 3.2% of patients in the alteplase arm. While definitive evidence of the superiority or non-inferiority of tenecteplase at a dose of 0.25 mg/kg versus alteplase in minor stroke requires an adequately powered randomised trial, the present data provide reassurance that tenecteplase likely provides similar efficacy and safety outcomes to alteplase in the population who had a minor stroke.

Finally, the study highlights that patients presenting with disabling minor deficits will often have visible occlusions on CT angiography. Patients who had a minor stroke with visible occlusions carry an elevated risk of early neurological deterioration and poorer functional outcomes. Overall, 51.3% of patients who had a minor stroke included in this secondary analysis had visible occlusions, and 5% of those were in a proximal large artery. These rates are higher than previous minor stroke studies, where the rate of any visible occlusion ranged from 5% to 15%. The reason for the higher rates of occlusions in this subgroup may reflect a bias of investigators to enrol and thrombolise those patients with minor deficits and visible occlusions due to concerns about progression. Study screening logs were not maintained, so it is not possible to confirm specifically which minor strokes were excluded. Future studies, such as the ongoing TEMPO-2 trial (ClinicalTrials.gov: NCT02398656), will more definitively determine if tenecteplase is superior to the standard of care, specifically in the population who had a minor stroke with visible occlusions.

**Limitations**

Our study has several limitations. First, randomisation was not stratified by baseline NIHSS; therefore, the effect of unmeasured confounders on the analysis cannot be discounted. Second, there were baseline differences in the number of patients with vessel occlusion and utilisation of endovascular thrombectomy between the groups, both higher in the tenecteplase group. Third, due to the pragmatic nature of the trial, no screening logs were maintained, and it was left to the discretion of enrolling physicians regarding which minor strokes to enrol. Since patients were enrolled based on current Canadian

### Table 3  Safety outcomes in study participants treated with tenecteplase versus alteplase

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>Tenecteplase (n=194), n (%)</th>
<th>Alteplase (n=184), n (%)</th>
<th>Unadjusted risk ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death within 90 days</td>
<td>11 (5.7)</td>
<td>20 (11.0)</td>
<td>0.99 (0.96 to 1.02)*</td>
</tr>
<tr>
<td>Symptomatic intracranial haemorrhage</td>
<td>5 (2.6)</td>
<td>6 (3.3)</td>
<td>0.79 (0.24 to 2.54)</td>
</tr>
<tr>
<td>Peripheral bleeding requiring blood transfusions</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>NA</td>
</tr>
<tr>
<td>Oroolingual angioedema</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
<td>0.94 (0.06 to 15.05)</td>
</tr>
<tr>
<td>Other</td>
<td>17 (8.8)</td>
<td>17 (9.2)</td>
<td>0.94 (0.49 to 1.80)</td>
</tr>
<tr>
<td>Imaging-identified haemorrhage</td>
<td>23 (11.9)</td>
<td>27 (14.7)</td>
<td>0.80 (0.48 to 1.35)</td>
</tr>
<tr>
<td>Subarachnoid haemorrhage</td>
<td>5 (2.6)</td>
<td>4 (2.2)</td>
<td>1.18 (0.32 to 4.34)</td>
</tr>
<tr>
<td>Subdural haemorrhage</td>
<td>0 (0)</td>
<td>1 (0.5)</td>
<td>NA</td>
</tr>
<tr>
<td>Intraventricular haemorrhage</td>
<td>5 (2.6)</td>
<td>3 (1.6)</td>
<td>1.58 (0.38 to 6.52)</td>
</tr>
<tr>
<td>H11 (scattered small petechiae)</td>
<td>1 (0.5)</td>
<td>5 (2.7)</td>
<td>0.18 (0.02 to 1.59)</td>
</tr>
<tr>
<td>H12 (confluent petechiae)</td>
<td>12 (6.2)</td>
<td>13 (7.1)</td>
<td>0.86 (0.40 to 1.84)</td>
</tr>
<tr>
<td>PH1 (haematoma occupying &lt;30% of infarct with no substantive mass effect)†</td>
<td>6 (3.1)</td>
<td>3 (1.6)</td>
<td>1.87 (0.47 to 7.39)</td>
</tr>
<tr>
<td>PH2 (haematoma occupying ≥30% of infarct with obvious mass effect)‡</td>
<td>2 (1)</td>
<td>3 (1.6)</td>
<td>0.62 (0.10 to 3.70)</td>
</tr>
</tbody>
</table>

Imaging-identified intracranial haemorrhages were assessed in a central core laboratory in a blinded manner and classified using the Heidelberg classification.

*HR using Cox proportional hazard adjusted for age, sex and occlusion site.
†Remote PH type 1 was defined as haematoma outside the infarcted tissue with no substantive mass effect.
‡Remote PH type 2 was defined as haematoma outside the infarcted tissue, with obvious mass effect.
HI, haemorrhagic infarction; NA, not applicable; PH, parenchymal haematoma.
guidelines for thrombolysis, most patients with minor strokes likely had disabling deficits, although this was not possible to confirm. Finally, this is a post-hoc secondary analysis that is inadequately powered to detect group differences in the primary and secondary outcomes. The results should be considered exploratory and hypothesis-generating.

Conclusions
In patients who had an acute stroke enrolled in the AcT Study presenting with minor deficits, safety and efficacy outcomes with tenecteplase 0.25 mg/kg were not significantly different from alteplase 0.9 mg/kg. In these patients, tenecteplase may be a reasonable alternative to alteplase for those meeting standard indications for thrombolysis; however, further adequately powered studies in the population who had a minor stroke are needed to confirm these results.

Author affiliations
1 Department of Medicine, Division of Neurology, University of Alberta, Edmonton, Alberta, Canada
2 Department of Internal Medicine, Division of Neurology, University of Manitoba, Winnipeg, Manitoba, Canada
3 Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
4 Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA
5 Department of Neurosciences, Radiology and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
6 Diagnostic and Interventional Neuroradiology, Tours University Hospital, Tours, France
7 Department of Clinical Neurosciences, University of Montreal, Montreal, Quebec, Canada
8 Department of Medicine, Queen Elizabeth Health Sciences Centre, Charlottetown, Edward Island, Canada
9 Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
10 Department of Medicine, Neurology Division, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
11 Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
12 Kelowna General Hospital, Kelowna, British Columbia, Canada
13 Department of Medicine, Medicine Hat Regional Hospital, Medicine Hat, Alberta, Canada
14 Department of Neurology, University of Toronto, Toronto, Ontario, Canada
15 Department of Neurosciences, University of British Columbia, Vancouver, British Columbia, Canada
16 Department of Medicine, Neurology Division, University of Manitoba, Winnipeg, Manitoba, Canada
17 Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
18 Division of Neurology, McMaster University, Hamilton, Ontario, Canada
19 Division of Neurology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Contributors RN and NS contributed equally as first authors. NS and BM had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. Concept and design—BB, RN, NS, BM, NA and AS. Acquisition, analysis or interpretation of data—SBC, AYP, HW, HK, GH, AT, HAMA, AP, TF, DD, LC, TS, MAA, RRS, NS, BB and BM. Drafting of the manuscript—RN, NS and BB. Critical revision of the manuscript for important intellectual content—MK, NA, RS, FB, SBC, MH, AYP, HW, AA, IA, FB, HK, GH, AT, HAMA, AP, TF, AD, LC, AS, TS, MAA, RRS and BM. Obtained funding—RRS and BM. Supervision—MAA, RRS, BM and BB. BM accepts full responsibility and is the guarantor for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

Funding Alberta Strategy for Patient Oriented Research Support Unit (N/A) and Canadian Institutes of Health Research (419722. 450890).

Competing interests TF has received consulting fees from Roche Canada and is on the board of DESTINE Health. SBC is the principal investigator for the TEMPO-2 trial for which Boehringer Ingelheim has provided in-kind support. BM has stock options in Circle NV and has consulted for Biogen and Boehringer Ingelheim. All other authors declare no competing interests.

Patient consent for publication Not required.

Ethics approval This study involves human participants. The trial used deferred consent procedures wherever approved by local research ethics boards at the 22 centres involved in the study. The individual ethics ID for each of 22 centres was not collected. Two centres, in the province of Quebec, Canada, used only prospective consent (written or verbal) from patients or their representatives. At the remaining centres where consent was deferred, patients or their legal representatives were asked to provide written or electronic informed consent as soon as possible after treatment, within 7 days of randomisation or before discharge, whichever was earlier. The process for consent was developed in consultation with an ethicist, a patient adviser, and a focus group involving patients and caregivers. This process is in accordance with the Tri-Council Policy Statement-Ethical Conduct for Research Involving Humans guidelines and the Helsinki Declaration, and reflects the imperative to treat patients quickly so as not to disadvantage enrolled patients compared with patients not enrolled in the trial.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data collected for the study, including de-identified individual participant data and a data dictionary defining each field in the set, can be made available to others upon reasonable request and after signing appropriate data sharing agreements by contacting the corresponding author. Such requests must be approved by the respective ethics boards and appropriate data custodians.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Mahesh Kate http://orcid.org/0000-0003-4794-2882
Fouzi Bala http://orcid.org/0000-0001-6748-2081
MacKenzie Horn http://orcid.org/0000-0002-1472-3977
Herbert Alejandro Manosalva Alzate http://orcid.org/0000-0001-8801-9248
Thalia Field http://orcid.org/0000-0002-1176-0633
Dar Dowlatshahi http://orcid.org/0000-0003-1379-3612
Ashfaq Shuaib http://orcid.org/0000-0002-3380-7068
Brian H Buck http://orcid.org/0000-0002-7984-6062

REFERENCES
1 Saber H, Saver JL. Distributional validity and Prognostic power of the National Institutes of health stroke scale in US administrative claims data. JAMA Neurol 2020;77:606–12.
4 Braksick SA, Wijdicks EF. An NIHSS of 0 and a very disabling indistinguishable stroke. Neurocrit Care 2017;26:444–5.
5 Smith EE, Fonnarow GC, Reeves MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant...
tissue-type plasminogen activator; findings from get with the guidelines-stroke. Stroke 2011;42:3110–5.
11 Braksačk SA, Rabinstein AA. Antiplatelets are enough for nondisabling strokes. JAMA Neurol 2023;80:1263.
Supplementary Appendix 1

1) AcT trial protocol v2.0
2) Statistical analysis plan
Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry based Pragmatic Randomized Controlled Trial

(The AcT RRCT)

Coordinating Centre
University of Calgary
Foothills Medical Center
1403 29th Street NW
Calgary, AB T2N 2T9

Sponsor
Governors of the University of Calgary

PROTOCOL AcT 02.0 ORIGINAL PROTOCOL

ISSUE DATE: May 23, 2021
GENERAL INFORMATION

Signatures of Approval

Protocol No. Act-02.0 Original Protocol (Draft)

Study Title: Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry based Pragmatic Randomized Controlled Trial

My signature below confirms that I have read and approved this protocol and assures that this clinical study will be conducted according to all requirements of this protocol, the Declaration of Helsinki, International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP), the Tri-Council Policy Statement (2), and any applicable regulatory requirements.

__________________________
Date

__________________________
Date

__________________________
Date

Name of Clinical Site:

Site Qualified/Principal Investigator:

Name
Title

__________________________
Date

Version 2.0
# Table of Contents

**Alteplase Compared to Tenecteplase in Patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry based Pragmatic Randomized Controlled Trial**  
(The ACT RRCT)  

1

**GENERAL INFORMATION**  

2

**Signatures of Approval**  

2

**Study Title:** Alteplase Compared to Tenecteplase in Patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry based Pragmatic Randomized Controlled Trial  

2

**Table of Contents**  

3

**List of Abbreviations**  

5

**Funding and Support in Kind**  

6

2. **Study Synopsis**  

7

3. **Coordinating Centre, Sponsor, Investigators and Facilities**  

8

4. **Background**  

9

4.1 **The Problem**  

9

4.2 **The Principal Research Question**  

9

4.3 **Why is a Trial Needed Now?**  

9

4.3.1 **The Evidence for Intravenous Alteplase in Patients with Acute Ischemic Stroke**  

10

4.3.2 **Issues Around Utilization of Intravenous Alteplase**  

10

4.3.3 **What is Tenecteplase?**  

11

4.3.4 **The Current Evidence Regarding Efficacy and Safety of Intravenous Tenecteplase**  

11

4.4 **Risks to the Safety of Participants Involved in the Trial**  

12

4.5 **Systematic Reviews and Meta-analysis**  

13

4.5.1 **Systematic Reviews**  

13

4.5.2 **Ongoing Trials**  

14

4.6 **How Will the Results of this Trial be Used?**  

14

5. **The Proposed Trial**  

15

5.1 **Trial Design**  

15

5.2 **Planned Trial Interventions**  

15

5.2.1 **Study Drugs**  

16

5.2.2. **Clinical and Imaging Evaluations**  

17

5.2.3 **Laboratory Evaluations**  

17

5.2.4 **Concomitant Medications**  

17

Version 2.0  

3
5.3 PROPOSED PRACTICAL ARRANGEMENTS FOR ALLOCATING PARTICIPANTS TO TRIAL GROUPS 17
5.4 CONSENT 18
5.5 PROPOSED METHODS FOR PROTECTING AGAINST SOURCES OF BIAS 20
5.6 INCLUSION/EXCLUSION CRITERIA 20
5.7 PROPOSED DURATION OF TREATMENT PERIOD 21
5.8 PROPOSED FREQUENCY AND DURATION OF FOLLOW UP 21
5.9 PRIMARY AND SECONDARY OUTCOME MEASURES 21
5.10 HOW WILL THE OUTCOMES BE MEASURED AT FOLLOW UP? 22
5.11 ADVERSE EVENT AND SERIOUS ADVERSE EVENTS REPORTING AND MANAGEMENT 22

6. STATISTICS 26
6.1 THE PROPOSED SAMPLE SIZE AND JUSTIFICATION 26
6.2 THE PLANNED RECRUITMENT RATE 27
6.3 PARTICIPANT COMPLIANCE MONITORING 27
6.4 RATE OF LOSS TO FOLLOW UP AND MISSING DATA 28
6.5 CENTERS INVOLVED 28
6.6 PROPOSED TYPES OF ANALYSES 28
6.7 PROPOSED FREQUENCY OF ANALYSES 29
6.8 PRE-SPECIFIED SUBGROUP ANALYSES 29

7. TRIAL MANAGEMENT 29
7.1 ARRANGEMENTS FOR DAY-TO-DAY MANAGEMENT OF THE TRIAL 29
7.2 DATA CONFIDENTIALITY 30
7.3 ETHICS 31
7.4 MONITORING 31
7.5.1 RETENTION OF DOCUMENTS 36
7.5.2 SOURCE DOCUMENTS 36
7.5.3 INSPECTIONS 37
7.6 DATA SAFETY MONITORING COMMITTEE 37
7.7 END OF TRIAL 37
7.8 ANCILLARY STUDIES AND PUBLICATION POLICY 37
7.9 DATA SHARING PLAN 38

8. REFERENCES 38

FIGURE 1: EXEMPLAR LABELLING OF INTRAVENOUS TENECTEPLASE AND INTRAVENOUS ALTEPLASE. 46

LINKAGE RATES FOR THE QUICR REGISTRY TO ADMINISTRATIVE DATASETS 48

BASED ON NOVEMBER 2018 QUICR EXTRACT 48
# List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>CRU</td>
<td>Clinical Research Unit</td>
</tr>
<tr>
<td>CSC</td>
<td>Comprehensive Stroke Centre</td>
</tr>
<tr>
<td>DSMC</td>
<td>Data and Safety Monitoring Committee</td>
</tr>
<tr>
<td>ED</td>
<td>Emergency Department</td>
</tr>
<tr>
<td>EVT</td>
<td>Endovascular treatment</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>IA</td>
<td>Intra-arterial</td>
</tr>
<tr>
<td>ICA</td>
<td>Internal Carotid Artery</td>
</tr>
<tr>
<td>ICH</td>
<td>Intracranial Hemorrhage</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>LVO</td>
<td>Large Vessel Occlusion</td>
</tr>
<tr>
<td>MCA</td>
<td>Middle Cerebral Artery</td>
</tr>
<tr>
<td>MI</td>
<td>Myocardial Infarction</td>
</tr>
<tr>
<td>MOP</td>
<td>Manual of Operating Procedures</td>
</tr>
<tr>
<td>mRS</td>
<td>Modified Rankin Scale</td>
</tr>
<tr>
<td>NIHSS</td>
<td>National Institutes of Health Stroke Scale</td>
</tr>
<tr>
<td>NINDS</td>
<td>National Institute of Neurological Disorders and Stroke</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised Controlled Trial</td>
</tr>
<tr>
<td>REB</td>
<td>Research Ethics Board</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SUADR</td>
<td>Serious Unexpected Adverse Drug Reaction</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>TICI</td>
<td>Thrombolysis in Cerebral Infarction Score</td>
</tr>
<tr>
<td>tPA</td>
<td>Tissue Plasminogen Activator</td>
</tr>
<tr>
<td>tNK</td>
<td>Tenecteplase</td>
</tr>
</tbody>
</table>
# RESEARCH REFERENCES

<table>
<thead>
<tr>
<th>Clinical trials.gov Number:</th>
<th>NCT03889249</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

# FUNDING AND SUPPORT IN KIND

<table>
<thead>
<tr>
<th>FUNDER(S)</th>
<th>FINANCIAL AND NON-FINANCIAL SUPPORT GIVEN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## 2. Study Synopsis

<table>
<thead>
<tr>
<th>Trial Title</th>
<th><strong>Alteplase Compared to Tenecteplase: QuICR &amp; OPTIMISE Registry based Randomized Controlled Trial</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Short Title</td>
<td>ACT-QuICR &amp; OPTIMISE</td>
</tr>
<tr>
<td>Clinical Phase</td>
<td>PHASE III</td>
</tr>
<tr>
<td>Trial Design</td>
<td>Randomized Open label Registry based trial with blinded end-point assessment</td>
</tr>
<tr>
<td>Trial Participants</td>
<td>Acute ischemic stroke patients eligible to receive IV alteplase as per current guidelines</td>
</tr>
<tr>
<td>Planned Sample Size</td>
<td>1600</td>
</tr>
<tr>
<td>Treatment duration</td>
<td>Single dose administration</td>
</tr>
<tr>
<td>Follow up duration</td>
<td>90 days</td>
</tr>
<tr>
<td>Planned Trial Period</td>
<td>3 years</td>
</tr>
<tr>
<td>Outcome Measures</td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>modified Rankin Scale (mRS) 0 or 1 at 90-120 days</td>
</tr>
</tbody>
</table>
| Secondary | • Discharge destination (home, early supported discharge, rehabilitation facility, long term care, death)  
• Home time  
• Actual 90-120 day mRS score  
• Door to needle time  
• Door-in-door-out (DIDO) times at the Primary Stroke Centre  
• Recanalization status (mTICI score) at first angiographic acquisition in patients taken to the angio-suite for the purpose of administering EVT  
• Proportion of patients administered EVT  
• Door-to-groin puncture time in patients undergoing EVT  
• CT-to-puncture time in patients undergoing EVT  
• Return to baseline level of functioning |
| Safety Outcomes | • Death within 90 days  
• Symptomatic ICH post-acute stroke treatment defined as per QuICR and OPTIMISE registries |
| Medicinal Products being tested | Tenecteplase (TNK-tPA)  
Alteplase (tPA) |
| Formulation, Dose, Route of Administration | IV tenecteplase 0.25 mg/kg (single bolus, maximum dose 25 mg) or IV alteplase 0.9 mg/kg (10% bolus & 90% as IV infusion over 1 hour, maximum 90 mg). |
## 3. Coordinating Centre, Sponsor, Investigators and Facilities

| **Coordinating Centre** | University of Calgary  
Foothills Medical Center  
1403 29th Street NW  
Calgary, AB T2N 2T9 |
|------------------------|----------------------------------------------------------------------|
| **Principal Investigator** | Bijoy K. Menon M.D., MSc, FRCPC  
University of Calgary  
Room 1049A, Foothills Medical Centre  
1403, 29th Street NW  
Calgary, AB, T2N 2T9  
Phone: 403-944-8107  
Fax: 403-283-2270  
Email: Bijoy.Menon@Albertahealthservices.ca |
| **Co-Principal Investigator** | Richard H. Swartz M.D., PhD FRCPC, University of Toronto |
| **Research Co-ordinator** | Carol Kenney RN CCRP  
University of Calgary |
| **Data Management Center** | University of Calgary Clinical Research Unit (CRU) and a designated vendor chosen by the sponsor  
Foothills Medical Center  
1403 29th Street NW  
Calgary, AB T2N 2T9 |
| **Executive** | Michael D. Hill, Brian Buck, Mayank Goyal, Mohammed Almekhlafi, Shelagh B. Coutts, Michel Shamy, Nancy Newcommon, Andrew M. Demchuk, Dar Dowlatshahi, Noreen Kamal, Moira Kapral, Mukul Sharma, Christiane Job McIntosh, Tolulope Sajobi |
4. Background

4.1 The Problem

There are two established therapies for acute ischemic stroke, namely intravenous alteplase and endovascular thrombectomy (EVT). The guiding principles behind these therapies are fast, effective and safe reperfusion of ischemic brain.\(^1\) Patients with acute ischemic stroke presenting within 4.5 hours from symptom onset are administered intravenous alteplase.\(^2\) If there is evidence of large vessel occlusion (LVO), these patients are transferred to the nearest comprehensive stroke center (CSC) for EVT.\(^3,4\) Physicians, hospitals and health systems are focused on implementing efficient triaging systems and workflow processes to improve speed and efficacy of administration of these life-saving therapies.\(^5,6\) Although efforts over the years with intravenous alteplase administration has resulted in improvement in efficiency metrics like door to needle time (DTN) and door-in-door-out (DIDO) time, these metrics are still not optimal, and the therapy is underutilized.\(^7,8\) Physicians continue to have concerns about low early reperfusion rates, increased risk of symptomatic intracerebral hemorrhage and challenges with drug administration (bolus + 60-minute infusion) with intravenous alteplase.

Recent phase II trials have shown that intravenous tenecteplase is potentially safer and may achieve higher early reperfusion rates than alteplase in patients with acute ischemic stroke.\(^10-12\) Bolus administration makes tenecteplase easier to administer than alteplase (which requires infusion pumps).\(^13\) Transfer of patients from primary stroke centers (PSC) to comprehensive stroke centers (CSCs) is potentially easier without infusion pumps. Moreover, depending on the province, tenecteplase either costs the same, or even less, than alteplase. It is therefore possible that the use of intravenous tenecteplase in patients with acute ischemic stroke otherwise eligible for intravenous alteplase may result in faster administration of thrombolysis and more efficient transport to CSCs, thus saving time, reducing adverse events (intracranial hemorrhage) and potentially improving patient outcomes, while saving the health system costs.\(^13\) For these various reasons, robust evidence that tenecteplase is non-inferior to alteplase as an intravenous thrombolytic agent in patients with acute ischemic stroke will change current clinical practice as it did in patients with myocardial infarction.\(^14\)

4.2 The principal research question

**In patients with acute ischemic stroke eligible for intravenous thrombolysis, is tenecteplase non-inferior to alteplase for 90-day functional independence assessed using the modified Rankin Scale?**

To answer this question, we propose a pragmatic, registry based, prospective, randomized, open label, blinded end point, controlled trial of intravenous tenecteplase vs. intravenous alteplase in patients with acute ischemic stroke otherwise eligible for intravenous thrombolysis as per current guidelines.

4.3 Why is a trial needed now?

The key arguments for the proposed trial are:
1) Intravenous alteplase (0.9 mg/kg body weight) has limited early efficacy in acute ischemic stroke patients with LVO and a known risk of intracranial hemorrhage. Many patients are not thrombolysed or still do not have good outcomes after thrombolysis.

2) Intravenous tenecteplase is used for myocardial infarction. Superior pharmacological properties suggest that it may have greater efficacy, a better safety profile and a substantially easier and more pragmatic mode of administration (bolus) compared to alteplase (bolus + infusion).

3) Dosing of tenecteplase has been studied. The optimum dose in patients with ischemic stroke may be 0.25 mg/kg body weight.

4) Safety of tenecteplase has been studied in phase II trials and one phase III trial. Phase II trials suggest that tenecteplase at a dose of 0.25 mg/kg body weight is potentially safer than alteplase.

5) Efficacy of tenecteplase has been studied for the intermediary outcome of early recanalization. A Phase II trial suggests that tenecteplase (0.25 mg/kg body weight) is superior to alteplase.

6) Registries are now in place to capture ischemic stroke patients treated with intravenous thrombolysis. A registry embedded randomized controlled trial (RRCT) is now possible, and the registries can be used pragmatically to test one thrombolytic agent against another.

4.3.1 The evidence for intravenous alteplase in patients with acute ischemic stroke

Intravenous (IV) thrombolysis with alteplase (single chain human recombinant tissue plasminogen activator) is the most widely used therapy in acute ischemic stroke patients presenting within the first 4.5 hours from symptom onset. The NINDS trial was the first RCT to show superiority of IV alteplase over placebo in improving clinical outcome when given within the first three hours of symptom onset. The ECASS III study further extended the treatment window up to 4.5 hours from symptom onset. The effect size was lower in patients treated beyond 3 hours with a Number Needed to Treat (NNT) increase by 1 for every 20 minutes delay in initiating alteplase. The value of faster thrombolysis was further emphasized in a patient level meta-analysis of all intravenous alteplase trials. This study demonstrated the time-dependent effectiveness of alteplase administration up to 4.5 hours from symptom onset. There was evidence of benefit in patients aged over 80, those with minor stroke deficits, and those with or without imaging documented intracranial occlusion. The rate of intracranial hemorrhage varied from 2.7% to 15.7% across the alteplase trials, depending on the definitions used for symptomatic hemorrhages in these different studies. The risk of alteplase related hemorrhage was higher among patients who had more severe strokes. The magnitude of benefit was dependent on the site of arterial occlusion with better recanalization seen in patients with distal occlusions.

4.3.2 Issues around utilization of intravenous alteplase

Despite evidence for efficacy of intravenous alteplase, extensive public and professional education campaigns, and enhanced quality of acute stroke facilities, the rates of alteplase use remain relatively low. Stroke symptoms may not always be easily recognizable, thus introducing delays in patients presenting to hospitals. Logistical issues including calculating separate bolus and infusion doses and arranging an infusion pump contribute to delay. Pharmacodynamic studies show that even a small delay between administration of bolus and start of infusion of intravenous alteplase reduces drug
The risk of intracranial hemorrhage with intravenous alteplase is small but real and can lead to significant morbidity or mortality. Many emergency physicians continue to remain skeptical about the safety of intravenous alteplase in patients with acute ischemic stroke, further leading to underutilization of this therapy.

Recent studies suggest that early recanalization rates with intravenous alteplase in patients with proximal arterial occlusions are very low. This relative lack of efficacy early in patients with more severe stroke together with an increased risk of intracranial hemorrhage has put pressure on health systems to bypass primary stroke centers (PSCs) en-route to comprehensive stroke centers (CSCs) for endovascular thrombectomy (EVT). Moreover, the specific logistics of administering alteplase (bolus and infusion) is a major reason for longer door in door out (DIDO) times in many primary stroke centers, further contributing to slower triage and transport and poorer outcomes in patients with disabling acute stroke.

### 4.3.3 What is Tenecteplase?

Tenecteplase is a recombinant fibrin-specific plasminogen activator derived from native t-PA by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus.

### 4.3.4 The current evidence regarding efficacy and safety of intravenous tenecteplase

In-vitro studies demonstrate that tenecteplase has superior thrombolytic ability when compared to alteplase. This could be because tenecteplase has higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) when compared to alteplase. The initial evidence supporting the use of tenecteplase in patients with acute ischemic stroke comes from a dose-escalation safety study of 88 patients in which a dose of 0.5 mg/kg body weight resulted in a significantly higher rate of symptomatic intracranial hemorrhage (15%, 2/13 patients). A subsequent adaptive dose-finding study found that a dose of 0.4 mg/kg body weight also resulted in a higher incidence of symptomatic intracranial hemorrhage (16%, 3/19 patients) and a lower rate of 24-hour major neurological improvement. A phase II trial compared two doses of tenecteplase (0.1 mg/kg or 0.25 mg/kg body weight) with intravenous alteplase (0.9 mg/kg body weight) in patients with acute ischemic stroke presenting within 6 hours of stroke symptom onset. Patients were selected using advanced imaging and an explanatory framework. Tenecteplase in both dose tiers was found to be superior to alteplase in achieving the co-primary outcome of reperfusion and mean NIHSS score improvement at 24 hours. Interestingly, the 0.25 mg/kg body weight dose was superior to the 0.1 mg/kg dose for all outcomes without increasing the risk of hemorrhage.

The single-arm TEMPO-1 trial that we led enrolled patients with minor non-disabling stroke symptoms and imaging documented evidence of intracranial occlusions to receive escalating doses of intravenous tenecteplase (0.1 and 0.25 mg/kg body weight). The rate of symptomatic intracranial hemorrhage in this study was 2% (1/50 patients).
The ATTEST trial was a single-center phase II trial that randomized 104 patients to receive intravenous tenecteplase (0.25 mg/kg body weight) vs. standard dose intravenous alteplase.\textsuperscript{12} The primary outcome was the proportion of penumbra salvaged (CT perfusion-defined penumbra volume at baseline minus CT infarct volume at 24–48 h). Despite prognostic imbalances at baseline with more negative imaging features in the tenecteplase group (a higher proportion of patients with large artery occlusion 75% vs. 61% and 33% larger ischemic core volume), there were trends towards earlier major neurological improvement and lower risk of intracranial hemorrhage in patients treated with tenecteplase.

The EXTEND-IA tNK trial (published in early 2018) was another phase II trial with an explanatory framework that enrolled 202 patients with CT-perfusion mismatch and proximal anterior circulation occlusions to receive intravenous tenecteplase (0.25 mg/kg body weight) vs. standard dose intravenous alteplase before being administered standard of care endovascular thrombectomy.\textsuperscript{17} The primary outcome (reperfusion of greater than 50% of the ischemic territory or an absence of retrievable thrombus assessed on initial catheter angiopathy assessment before endovascular thrombectomy) occurred in 22% of patients receiving intravenous tenecteplase compared to 10% of patients receiving standard dose intravenous alteplase (rate ratio 2.2; 95% CI, 1.1 to 4.4; \(P=0.002\) for noninferiority, \(P=0.03\) for superiority). In secondary analysis, patients receiving intravenous tenecteplase fared better clinically compared to patients receiving alteplase (median mRS 2 vs. 3, respectively at 90 days, common odds ratio, 1.7; 95% CI, 1.0 to 2.8; \(P=0.04\)). The rate of symptomatic intracranial hemorrhage was 1% in both groups. The trial results suggest that by achieving higher earlier recanalization rates, intravenous tenecteplase is potentially capable of achieving better clinical outcomes in patients who are otherwise candidates for endovascular thrombectomy.

Finally, the only phase III trial that compared intravenous tenecteplase to standard dose alteplase was the Norwegian Tenecteplase Stroke Trial (NOR-TEST) trial.\textsuperscript{16} This trial randomized 1100 patients using standard thrombolysis eligibility criteria to test if intravenous tenecteplase (at a dose of 0.4 mg/kg body weight) was superior to standard dose alteplase. The trial failed to meet its primary outcome with 64% achieving mRS 0-1 at 90 days in the tenecteplase group vs. 63% in the alteplase group (odds ratio 1.08, 95% CI 0.84 to 1.38). The trial was critiqued for a) including a large proportion of patients with mild stroke symptoms and stroke mimics (median NIHSS 4 suggesting that almost 50% of the enrolled sample may not have been the ideal target population for thrombolysis) and b) being powered only to detect superiority but not non-inferiority of tenecteplase vs. standard dose alteplase.\textsuperscript{27} Moreover, the rate of symptomatic intracranial hemorrhage in the tenecteplase arm was slightly higher than that in the alteplase arm (3% vs. 2%), likely due to the higher dose of tenecteplase (0.4 mg/kg body weight) used in that trial. The Act trial we propose is powered to detect non-inferiority. It will also include a more representative group of acute stroke patients. Data from the QuICR registry shows that the median NIHSS in all patients (n=592) who received thrombolysis within that registry in the year 2018 was 11 (significantly more severe strokes than in the NORTEST trial); moreover, the ongoing TEMPO 2 trial and the routine use of vascular imaging to help guide care in Canada will also limit enrolment of patients with mild non-disabling stroke symptoms and stroke mimics in the proposed trial.\textsuperscript{13}

4.4 Risks to the safety of participants involved in the trial
Although recent phase II clinical trials have shown that intravenous tenecteplase at a dose of 0.25 mg/kg body weight is potentially safer than the current standard of care i.e. intravenous alteplase, the risk of hemorrhage, both intracranial and systemic exists (approximately 4 to 5% with either drug). Angioedema occurs after both alteplase and tenecteplase in a small proportion of patients. The incidence of severe angioedema in alteplase-treated patients is approximately 1%. Other adverse events associated with both alteplase and tenecteplase are extra-cranial hemorrhage (<1%) and transient hypotension (~0.1%). Although there is less empiric experience with the use of tenecteplase in ischemic stroke, these risks are thought to be either identical or less with tenecteplase. It is unlikely therefore that there may be any additional risks to the safety of participants involved in the trial.

4.5 Systematic Reviews and Meta-analysis

4.5.1 Systematic Reviews

Four small phase II trials and one phase III trial have been completed to date. These trials have been heterogenous in design and patient selection strategies. Some of the trials have been dose escalation studies, others have used advanced CT Perfusion imaging criteria for patient selection or enrolled patients with mild strokes and stroke mimics predominantly. The bulk of the evidence comes from one large phase III trial (NORTTEST; 75% of all patients enrolled to date in any trial) that used tNK at a dose of 0.4 mg/kg body weight. A recent trial level meta-analysis showed that patients enrolled in these trials, on average, had significantly less severe strokes (mean baseline NIHSS ~ 6.8) when compared to patients enrolled in all the alteplase vs. placebo trials to date (median baseline NIHSS 12). Moreover, 15% of patients enrolled in the tNK vs. alteplase trials were stroke mimics. Other differences in baseline characteristics like under-representation of females (40% in the tNK trials overall vs. 45% in the alteplase trials) and lower incidence of atrial fibrillation (14% in the tNK trials vs. 24% in the alteplase trials) all suggest that on average, the sampling frame of patients included in the tNK vs. alteplase trial level meta-analysis is not representative of patients with acute stroke treated with intravenous alteplase. Acknowledging these limitations, when analysing mRS 0-1 at 90 days as outcome, a meta-analysis of the five trials shows unadjusted rates of tNK vs. alteplase of 57.9% vs. 55.4%; random-effects meta-analysis risk difference of 4% (95% CI minus 1% to + 8%). Interestingly, the rate of mRS 0-1 in the alteplase arm (55.4%) is significantly higher than that seen in the alteplase arm (~35%) of the patient level meta-analysis of alteplase vs. control trials; attesting to the significantly lower risk patients included in the tNK vs. alteplase trials to date. When assessing safety, the same trial level meta-analysis shows unadjusted rates of symptomatic ICH with tNK of 3.3% alteplase 3.2% with an adjusted risk difference of 0% (95% CI minus 1% to + 2%). Overall therefore, current AHA Stroke guidelines assign a Class (Strength) of recommendation IIb and Level (Quality) of Evidence B-R (moderate quality from meta-analyses of moderate quality RCTs) for intravenous tNK in patients with acute ischemic stroke. A recent editorial therefore concludes “We look forward to and encourage the stroke community to participate in active and future stroke trials with tenecteplase”
4.5.2 Ongoing trials

The ATTEST 2 phase III trial (NCT02814409) based in the UK has less rigid inclusion criteria but also excludes patients who in the opinion of the treating physician may benefit from endovascular thrombectomy. The trial plans to recruit 1800 patients.

The Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) trial (ACTRN1261300243718) is a randomized controlled phase III trial that uses advanced perfusion-imaging based selection criteria to test if tenecteplase at a dose of 0.25mg/kg body weight is superior to standard dose alteplase. The trial excludes patients with large vessel occlusions eligible for EVT and only includes patients who fulfill strict tissue-based imaging criteria.

The EXTEND IA-tNK 2 trial (NCT03340493) is an Australian phase II trial that is testing efficacy and safety of higher dose tenecteplase (0.4 mg/kg body weight) vs. tenecteplase (0.25 mg/kg body weight) in patients who are candidates for endovascular thrombectomy.

The TEMPO-2 trial (NCT02398656; CIHR funded and led by our group) is a multicenter, randomized, open-label, controlled trial of intravenous tenecteplase (0.25 mg/kg body weight) versus standard of care antiplatelet therapy in patients with TIA or minor strokes and imaging documented intracranial occlusion. The trial plans to recruit 1274 patients.

Finally, the TWIST trial (NCT03181360) is a phase III trial testing the efficacy of intravenous tenecteplase (0.25 mg/kg body weight) vs. standard care in patients waking up with stroke symptoms who are otherwise not eligible for intravenous alteplase.

None of the ongoing trials are addressing the primary question whether intravenous tenecteplase can replace intravenous alteplase as standard thrombolytic therapy in all patients who are currently eligible for intravenous thrombolysis.

The results of the proposed AcT trial are also more likely to be externally valid and therefore generalizable to Canadian current clinical practice than these other trials.33 An assessment of the AcT trial using the PRECIS-2 framework (https://www.precis-2.org; see adjacent figure) attests to external validity and generalizability.

4.6 How will the results of this trial be used?

Results from the proposed trial are likely to provide real life confirmatory evidence about the efficacy of intravenous tenecteplase in patients with acute ischemic stroke eligible for intravenous thrombolysis as per current guidelines. If the proposed trial demonstrates non-inferiority of intravenous tenecteplase when compared to alteplase, it
is likely to change clinical practice. Given relative ease of administration of tenecteplase (bolus only) vs. alteplase (bolus + infusion), workflow metrics in acute stroke like door-in-door-out (DIDO) time, door to needle (DTN) and door to reperfusion time can all potentially improve, thus improving clinical outcomes. In addition, better reperfusion rates and potentially better safety data is likely to increase utilization of thrombolytic therapy overall while at the same time potentially decreasing the need for resource intensive endovascular thrombectomy in many patients.

5. The Proposed Trial

5.1 Trial design

The proposed trial is a pragmatic, registry based, prospective, randomized (1:1) controlled, open-label parallel group clinical trial with blinded endpoint assessment of 1600 patients to test if intravenous tenecteplase (0.25 mg/kg body weight, max dose 25 mg) is non-inferior to intravenous alteplase (0.9 mg/kg body weight, max dose 90 mg) in patients with acute ischemic stroke otherwise eligible for intravenous thrombolysis as per standard care.

The trial will be embedded within the QuICR and the OPTIMISE registries. It will use linkages to administrative datasets to collect relevant data not available through the registries.

QuICR (https://www.ucalgary.ca/quicr/) is a cloud-based registry that collects data on all ischemic stroke patients receiving thrombolysis and/or endovascular treatment in Alberta. Currently, all stroke centres in Alberta and one primary stroke center (PSC) in Saskatchewan are contributing to the registry. The registry includes 15 PSCs that provide intravenous thrombolysis treatment only, and 2 Comprehensive Stroke Centres (CSCs) that provide both thrombolysis treatment and endovascular treatment. If possible, we will also utilize the Stroke Ambulance centred in Edmonton at the University of Alberta Hospital (16th PSC) and the Northern Alberta tele-stroke network (currently participating in QuICR).

OPTIMISE is a national registry supported by the Canadian Stroke Consortium to support the implementation and quality control for endovascular therapy (and more recently intravenous thrombolysis) among patients with acute ischemic stroke. The data collection fields in OPTIMISE were designed to mirror the QuICR registry. Data is captured using a web-based electronic data capture and reporting system and housed on a secure server at the Population Health Research Institute (PHRI) at McMaster University.

All sites participating in QuICR will participate in the trial. Sites participating in OPTIMISE and collecting data on all thrombolysis patients will also participate in the trial. In addition, other CSCs or PSCs in Canada that agree to participate in either the QuICR or the OPTIMISE registries or have similar infrastructure will also be eligible to participate in the trial.

5.2 Planned trial interventions

The intervention group will receive intravenous tenecteplase as a single bolus at a dose of 0.25 mg/kg body weight (maximum dose 25 mg) as soon as possible after randomization.
The control group will receive standard of care dosing of intravenous alteplase (0.9 mg/kg body weight, 10% bolus and 90% infusion as per standard care, maximum dose 90 mg).

All patients will have standard of care medical management on an acute stroke unit. There are no additional trial specific management recommendations.

5.2.1 Study Drugs

Intravenous tenecteplase: The trade name for tenecteplase is TNKase™ in Canada.

TNKase™ is available as 50mg vials. Each 50mg vial of TNKase™ is packaged with one 10ml vial of sterile water for injection for reconstitution. Reconstitution of 50mg of tenecteplase in 10 ml of sterile water results in a solution concentration of 5mg/ml.

Intravenous alteplase: The trade name for alteplase is ACTIVASE™ in Canada. This thrombolytic agent is the current standard care.

ACTIVASE™ is reconstituted by aseptically adding to the vial the appropriate volume of sterile Water for Injection, (100 mL for 100 mg vials) resulting in a solution concentration of 1mg/ml.

5.2.1.1. Drug Labelling

The trial is testing a standard, off-the-shelf drug (alteplase) vs. another off-the-shelf drug (tenecteplase) currently used for another indication i.e. acute myocardial infarction. The drug packages describe the expiration date of the drug, the recommended storage conditions, the drug reconstitution method and the LOT number. An Investigational Status Assessment (ISA) has been completed for use of alteplase; therefore, no labeling is required for alteplase drug packages. The sponsor will provide labels and the site PI will ensure that the tenecteplase drug packages are labelled as investigational with the current protocol version. The labels will also have the drug dosage as per current protocol and the name and address of the sponsor (See Appendix for Drug labels). To facilitate labelling and integration with clinical workflow, the sponsor can help sites make a “stroke kit” available, stocked with labelled tenecteplase and alteplase. In addition, copies of the mixing and dosing chart can be made available to sites as posters. Finally, the randomizer (text or web based) will also provide instructions on mixing and dosing.

5.2.1.2 Drug Traceability

Sites will be collecting LOT numbers and expiry date of the vial of drug administered to a patient and entering these numbers into the study database by study ID number. Pharmacy Drug Recall records are able to track LOT Numbers, expiry, vendor and patient name using a logic match.

5.2.1.3 Drug Storage/Temperature Monitoring
Both drugs are kept in environmentally controlled conditions i.e. a hospital, by hospital pharmacies, according to the information on the current drug labels, and made available for use as required. The current label on storage requirement for tenecteplase mentions that the drug may be stored at room temperature not to exceed 30°C. Environmentally controlled conditions in the participating hospitals ensure such storage conditions for current clinical use of tenecteplase.

5.2.2. Clinical and Imaging Evaluations

There are no trial specific clinical and imaging evaluations except as per standard care. 90-120 day outcome using the modified Rankin Scale and EQ-5D-5L will be collected by the trial in coordination with the site. All other data will be collected either through the QuICR and OPTIMISE registries or through administrative data linkages. (See sections 5.11, 7.4 and Appendix)

5.2.3 Laboratory Evaluations

There are no trial specific laboratory evaluations and no central laboratory. All laboratory evaluations are as per standard care only.

5.2.4 Concomitant medications

Standards of care applicable to any patient receiving intravenous alteplase apply to patients in both arms of the trial. There are no prohibited medications except those considered as such based on best practices.

5.3 Proposed practical arrangements for allocating participants to trial groups

Eligible patients will be randomized in a 1:1 ratio. Randomization will use a validated minimal sufficient balance (MSB) algorithm, to assure balance by site. The algorithm will kick in after the site has enrolled 5 subjects. The standard distribution is 50-50, but when an imbalance is detected with a p-value less than 0.3, the distribution changes to 65-35 in the direction against the imbalance. Randomization will be centralized, secure and concealed using a real-time web-based server, thus eliminating the possibility of confounding due to allocation bias. The central server will be linked to a randomization mechanism and will only be able to allocate one patient to either arm of the trial at one time. Investigators will be able to rapidly access the randomizer through a secure internet web browser or secure automated phone number or text message. Investigators will have to enter a site-specific ID number followed by an Investigator specific ID number and the weight of the patient in kilograms. They will then receive the drug allocation (tenecteplase vs. alteplase) along with unique study subject ID and the calculated drug dosage. They will later be prompted to enter if a) the correct drug was administered b) the correct dose was administered and c) the vial LOT number and expiry date of the administered drug.

Emails will be sent from the central trial server to site investigators and trial personnel with the site ID, unique study subject ID and drug allocation (study enrolment form). A copy of this email can be
printed and included in the patient chart. In addition, this email will also have a PDF checklist reminding site co-ordinators to ensure the following:

1. The study enrolment form is placed in the clinical patient chart
2. The patient and surrogate contact information is documented in the checklist
3. Consent is obtained (see section 5.4) and documented in the study database
4. The unique study subject ID and registry ID are entered in the study database
5. Report any serious adverse events occurring within the first 24 hours of randomization. This information will be documented on paper and/or in the study database

Each site will maintain a patient log that will include the above checklist, a copy of the patient enrolment form and patient or surrogate consent forms (if not obtained electronically; see section 5.4 Consent). The central trial coordinator and/or the automated study database application will contact the site registry coordinator within 7-10 days of enrolment to ensure the above steps are complete. A manual of procedures (MOP) will be made available to each participating site detailing all the steps above.

5.4 Consent

Where approved by the local research ethics board (REB), to reduce time to treatment, patients will be randomized using a deferral of consent procedure. The responsible treating physician will determine patient eligibility for the trial and initiate randomization if the patient is deemed eligible for the trial.

All patients will be enrolled by deferred consent. This study design respects TCPS2 guidelines and reflects the imperative to treat patients quickly, so as not to bias results or disadvantage enrolled patients compared to patients not enrolled in the trial. Because of this design, we will institute the following patient protections: 1. Identify a specific ethics lead (Dr. Michel Shamy, a stroke neurologist and ethics researcher from the University of Ottawa), a patient engagement expert (Dr. Job McIntosh, Alberta Health Services) and a patient/caregiver lead; 2. Develop a patient-oriented, 1-page information sheet for patients and their families at the time of enrollment (the information sheet); 3. Develop a patient-oriented, 2-page consent form for patients and their families regarding ongoing participation in the trial; 4. Develop a questionnaire to be administered to a sample of enrolled patients about their experiences with and attitudes towards deferred consent; 5. Hold a focus group with stroke patients to review the trial protocol and above documents prior to initiation of the trial. Past precedence with the ESCAPE trial (Shamy MCF et al; Deferral of Consent in Acute Stroke Trials: Lessons from the ESCAPE Trial. Stroke 2019; in press) suggest that deferral of consent is practical at all sites.

A detailed document outlining justification for deferred consent based on the Declaration of Helsinki Article 26 and Article 3.8 of the Tri-council Policy Statement-2 is available for enrolling sites. It is recommended that consent be obtained from subjects or their surrogates within 7 days of randomization or before discharge, whichever is earlier. In patients who die, and consent has yet to be obtained, reasonable efforts should be made to obtain consent from their surrogates. If consent could not be obtained in spite of best efforts (no surrogate or surrogate cannot be contacted), the patient will continue
in the trial. Subjects or, if incapacitated, their legal representatives, will have the right to withdraw from further participation (including long-term follow-up by record linkage). Subjects may withdraw consent for further contact but continue follow-up via record linkage. In the event that consent is withdrawn, data collected up until the point of withdrawal will be used for analysis.

We will provide an option for a site-specific electronic consent application with electronic signature support that will be linked to the randomization tool. This solution shall be made available via a secure web-application. Alternatively, sites can print the consent form from the site and upload a scanned signed paper version. The deferred consent capture process shall consist of the following steps:

1) An electronic or paper physician script will be made available to the physician prior to enrolling a patient in the trial. This script will contain information that the physician can use as guideline to help inform the patient/shared decision maker (SDM) about the trial. The use of this physician script is not mandatory;

2) An electronic or paper information sheet will also be made available to the physician to help him/her inform the patient or shared decision maker (SDM) about the trial.

3) If and when the patient is capable of communicating and/or the SDM is available, the physician will provide them with the information in the sheet above. It is recognized that sharing of the information sheet with patient/SDM may happen before, during or after randomization;

4) After randomization has been completed for a patient, a unique identifier (study ID) will be assigned to each patient by the application, shown on-screen to the physician or site-coordinator and sent via e-mail to the site co-ordinator;

5) After treatment has been administered, as an added quality assurance step, a randomization validation process will be initiated. This process will confirm whether the drug and dosage used match the randomization values and, if the trial information sheet was shown to the patient and/or SDM;

6) Once the randomization process has been completed, in conjunction with the validation exercise, the site co-ordinator shall connect to the electronic consent capture application via a PC, tablet, or web-enabled mobile phone;

7) The site co-ordinator will be asked to provide the unique patient identifier and their own user identifier; additionally, the site co-ordinator will select whether consent will be provided by the patient or a surrogate, and whether electronic or paper-based consent will be provided;

8) The system will check to ensure the validity of the identifiers and then will show the relevant (site-specific) consent information to the participant;

a. If electronic consent was selected, the participant will then be asked to review the information and, if they consent, validate/check the acknowledgement box, enter their name, date, month and year of birth, signature, and submit the form.

   i. The date of birth option can be disabled, if required/request by the REB review process

b. As a secondary consent capture method, the patient may choose to instead use a paper form, email or phone consent as approved by local ethics boards. If a patient chooses this option, the qualified site personnel will present the patient with a paper form with the same information as the electronic one. Once the patient fills-out this form, they will then enter the patient’s unique consent id and then scan and upload the form to the electronic consent application. Either consent method shall be deemed to sufficiently satisfy the consent requirements.
9) Once submitted, the application will securely store the consent information and associated signature in a secure database and file store.

10) This information can then be reviewed by auditors or authorized personnel by requesting it of the Clinical Research Unit.

11) If subjects or, if incapacitated, their legal representatives, withdraw from further participation (including long-term follow-up by record linkage), sites will inform the sponsor about this within 7 days of this happening. Subjects may withdraw consent for further contact but continue follow-up via record linkage. In the event that consent is withdrawn, data collected up until the point of withdrawal will be used for analysis. The site will update the patient consent log and inform the sponsor of the same.

The policies and procedures will receive prior review and approval by the IRB/REB of all hospitals to which prospective trial subjects may be admitted. These IRB/REBs will provide ongoing oversight of the trial.

During the conduct of the trial, a publicly accessible website will be available to provide information about the trial; and after the trial’s completion, the community will be notified of its outcome. The trial is also registered at www.clinicaltrials.gov.

5.5 Proposed methods for protecting against sources of bias

The trial will have allocation concealment and blinded endpoint assessment. Given the time sensitive nature of acute stroke treatment, blinding the enrolling health personnel and patient to treatment allocation is not practical. Primary clinical outcome data (assessed using the modified Rankin Scale) will be determined by the Rankin Focused Assessment (RFA) method\textsuperscript{34} using centralized telephone interviews conducted by central trial personnel blinded to treatment allocation. The trial coordinator may contact the site to help schedule phone follow-ups. Follow-ups will be scheduled 90 to 120 days after randomization. The manual of procedures (MOP) will describe in detail the Rankin Focused Assessment method for use by central trial personnel.

5.6 Inclusion/exclusion criteria

The proposed trial will recruit patients from the emergency departments of the hospitals participating in the QuICR and OPTIMISE registries.

\textbf{Inclusion Criteria}

Inclusion criteria is pragmatic. All patients with acute ischemic stroke eligible to receive intravenous alteplase as per standard care will be eligible for enrolment in the proposed trial. Patients eligible for endovascular thrombectomy in addition to intravenous thrombolysis are eligible for enrolment.

\textbf{Exclusion Criteria}

Contra-indications to intravenous thrombolysis as used by treating physicians as current standard of care apply.
The benefits of thrombolysis with intravenous alteplase in the pediatric population is unknown. Any patient < 18 years of age may therefore not be enrolled.

Women with pregnancy known to the investigator by history or examination, without requiring pregnancy testing, may only be enrolled in consultation with an expert stroke physician (either in person or through tele-stroke)\textsuperscript{35}

5.7 Proposed duration of treatment period

All eligible patients will receive the allocated intravenous thrombolytic therapy (tenecteplase or alteplase) acutely as a one-time treatment. Intravenous tenecteplase is administered as a single bolus injection over 5 to 10 seconds while intravenous alteplase is administered as a bolus over 1 minute followed by an infusion over approximately 60 minutes. There are no additional planned co-interventions throughout the duration of the trial.

5.8 Proposed frequency and duration of follow up

Duration of follow-up will be 90 days, up to 120 days. The primary outcome (mRS) will be collected at the end of follow-up (ideally at 90 days but definitely within 120 days).

5.9 Primary and secondary outcome measures

Primary Outcome: modified Rankin Scale 0-1 at 90 - 120 days

Secondary Outcomes:

1. Discharge destination (home, early supported discharge, rehabilitation facility, long term care, death) * #
2. Home time (defined as number of days subject spends at home after index stroke event)\textsuperscript{36}
3. Actual 90-120 day mRS score*#
4. Door to needle time*#
5. Door-in-door-out (DIDO) times at Primary Stroke Centres*#
6. Recanalization status (mTICI score) at first angiographic acquisition in patients taken to the angio-suite for the purpose of administering EVT*#
7. Proportion of patients administered EVT *#
8. Door-to-groin puncture time in patients undergoing EVT*#
9. CT-to-puncture time in patients undergoing EVT*#
10. Return to baseline level of functioning

Safety Outcomes:

1. Death within 90 days*#
2. Symptomatic ICH post-acute stroke treatment defined (As defined in the MOP)*Indicates data collected in the QuICR registry # Indicates data collected in OPTIMISE registry

5.10 How will the outcomes be measured at follow up?

The primary outcome (assessed using the modified Rankin Scale) will be determined by the Rankin Focused Assessment (RFA) method using centralized telephone interview by trained study personnel blinded to treatment allocation. The Rankin Focused Assessment consists of a 4-page form, accompanied by a 5-page Instructions. Details will be provided in the MOP.

Secondary outcome measures described above are all available through the QuICR and OPTIMISE registries and will be collected from those data sources. The home time outcome will be determined through linkage with administrative data to calculate the total time in the first 90 days after index event that a stroke patient is not an inpatient. Processes for administrative linkages within Alberta, Ontario and potentially other participating sites will be different based on local resources and policies. Return to baseline level of functioning will be determined using the same centralized telephone interview used to determine the primary outcome. Cognition will be assessed using an on-line assessment platform, with a login by Trial ID (no personal ID provided to the cognitive platform) and the cognitive data output to the trial database by Trial ID. These strategies and methods will be detailed in a manual of operations.

Primary safety outcomes death and symptomatic ICH will be collected through the trial database

5.11 Adverse event and Serious Adverse Events Reporting and Management

Definitions

An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Adverse events occur after enrolment and are defined as not being present prior to enrolment.

Serious adverse events (SAEs) are a subset of adverse events that are life threatening, require a surgical or medical procedure to prevent disability or death, result in admission to hospital, prolongation of hospitalization or transfer to an ICU, or results in death. A SAE can also be an important medical event that may not result in death, be life-threatening, or require hospitalization, but may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. A SAE is also an event that results in a congenital anomaly or birth defect.

The pharmacology and risks of alteplase in patients with acute ischemic stroke are well known; in addition, there are multiple recent phase II and one recent phase III trial attesting to the safety of intravenous tenecteplase in patients with acute ischemic stroke. Of note, in particular is the Norwegian Tenecteplase Stroke Trial (NOR-TEST) trial. This Phase III trial randomized 1100 patients using standard thrombolysis eligibility criteria to test if intravenous tenecteplase (at a dose of 0.4 mg/kg body weight) was superior to standard dose alteplase. The dose of intravenous tenecteplase
used in the NORTEST trial was higher than that proposed in this trial (0.25 mg/kg body weight, maximum dose 25 mg) while the dose of intravenous alteplase was the same as in this trial. The table below lists SAEs noted in the NORTEST trial in patients administered intravenous alteplase or intravenous tenecteplase. There was no difference in incidence of SAEs up until day 90 or patients affected by at least one SAE up until day 7. The NORTEST trialists reported the following SAEs, namely, any intracerebral hemorrhage, symptomatic intracerebral hemorrhage, death, angioedema, recurrence of ischemic stroke, epistaxis, chest pain, gastrointestinal bleeding, other extracranial bleeding and readmission as possibly or probably related to drug administration (see Table below). There were no differences in any of these expected SAEs between patients administered intravenous tenecteplase vs. alteplase.

Based on data from the NORTEST phase III trial and other recent phase II trials in acute ischemic stroke patients and based on substantial literature attesting to the safety of intravenous tenecteplase in patients with acute myocardial infarction for over 15 years, unexpected serious adverse drug reactions or events are unlikely in the trial. (See Table below for a list of SAEs from the NORTEST trial and Appendix, Table 1 for a list of expected adverse drug reactions that have been well described associated with stroke thrombolysis). The natural history of acute stroke is such that high morbidity is expected (See Appendix Table 1). Since both thrombolytic agents have a biological half-life measured in hours, treatment-related morbidity and AEs will occur within a short interval after administration.
Table above shows a list of SAEs in the intravenous tenecteplase vs. intravenous alteplase arms of the NORTEST trial.

Investigators are directed to the following product monographs for expected adverse drug reactions of alteplase and tenecteplase.

1. Alteplase (Activase)

   [http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Activase/Activase_AIS_PM_E.pdf](http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Activase/Activase_AIS_PM_E.pdf)

2. Tenecteplase (TNKase™)
http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/TNKase/TNKase_PM_E.pdf

The trial intends to obtain AE and SAE data through a combination of a) the study database b) the ongoing QuICR and OPTIMISE registries and c) through linkages to administrative data sources. The following AEs/SAEs that occur during hospital stay are captured in the QuICR* and OPTIMISE# registries.

- Urinary tract infection*
- Pneumonia*
- Deep venous thrombosis*
- External ventricular drain placement*
- Recurrent stroke*
- Hemicraniectomy*
- Sub-occipital craniectomy*
- Symptomatic intracerebral hemorrhage*#
- Intracerebral Hemorrhage*
- Groin or arterial access site hematoma#
- Endovascular procedure-related vessel perforation#
- Endovascular procedure-related vessel dissection#

*Indicates data collected in the QuICR registry
# Indicates data collected in OPTIMISE registry

Table 1 in the Appendix represents an empiric last of AEs and SAEs derived from the pooled database of multiple clinical trials. These are published, known adverse events associated with stroke because these are control arm patients only. The combined list above and the list in the Appendix will all be considered EXPECTED adverse events for the trial.

The following steps will be used to collect data on the above adverse events:

1. Given the short half-life of both thrombolytic agents (tenecteplase and alteplase) and known safety profile, adverse events occurring within the first 24 hours attributable (related) to either agent that correspond to known effects of these drugs or of hyperacute stroke (Appendix, Table 1) will be considered expected. Adverse events that occur beyond 24 hours will be considered unrelated to study drug.
2. Data on SAEs occurring within the first 24 hours including SAEs of special interest for the study, namely, a) symptomatic intracerebral hemorrhage (post-acute stroke treatment defined as per QuICR and OPTIMISE registries) b) angioedema and c) peripheral bleeding requiring blood transfusion will be collected through the trial database.
3. AEs measured routinely by the QuICR and OPTIMISE registries (highlighted as * or # above) will be collected from those registries.
4. Administrative data linkages will be used to collect data on other AEs. The Canadian Discharge Abstract Database (DAD) captures all hospital separations for all Canadian provinces and versions.
territories, with the exception of the province of Quebec. Each hospital discharge record includes up to 25 diagnosis codes, recorded using the ICD coding system, along with other clinical and demographic information. In addition, each diagnosis field in the database has an accompanying single digit field for the diagnosis type that is recorded whenever a diagnosis is recorded. The diagnosis type codes are as follows: type M: most responsible diagnosis; type 1: preexisting conditions (comorbidities) that influence care, or the hospital stay; type 2: conditions that arose after admission and that may thus represent complications of care; and type 3: preexisting conditions (comorbidities) that do not influence care, or the hospital stay. Type 2 diagnosis type codes will be used primarily to identify any AEs. Other data elements as relevant (interventions offered during admission; Group 11 or Blood transfusion given; Group 17) will also be collected. It will therefore not be possible to classify seriousness when data are obtained through administrative data linkages. Details on the data elements collected through DAD in each province will be made available in the MOP. The nature of the specific data linkages will be different in different jurisdictions (Alberta vs. Ontario). Data will be queried and obtained at regular intervals through the duration of the trial from the above data sources.

5. Although we predict that there will be no adverse events that will be classified as serious, unexpected and related, we will maintain constant contact with investigators to manage this rare possibility. Investigators are under obligation under the Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law) (Canada), to report potential Serious Unexpected Adverse Drug Reactions (SUADR) and we will utilize our relationship with the sites to identify any event that fits this definition.

The Trial Safety Committee will review unblinded safety data throughout the trial to ensure that events are being reported and they fall within accepted norms for routine stroke care. The DSMC will periodically review unblinded overall safety data to determine patterns and trends of events, or to identify safety issues, which would not be apparent on an individual case basis. Details of the DSMC review are outlined in the DSMC Charter. Management of AEs will be as per local jurisdictions.

6. Statistics

6.1 The proposed sample size and justification

The primary endpoint is the proportion of subjects that achieve a 90-day score of 0 or 1 on the mRS scale in both arms. The choice of this dichotomous outcome is based on clinical acceptance, an assessment of the distribution of mRS in the individual patient level meta-analysis and the choice of similar outcome in most ongoing trials.

A total of 1600 subjects will be randomly assigned to receive either intravenous tenecteplase or alteplase in a 1:1 ratio. Based on prior literature, we assume that the incidence of primary outcome (mRS 0-1) 90 days after randomization will be 38% and 35% respectively. Assuming a one-side non-inferiority margin of 5%, a one-sided significance Type I error of 2.5% and 90% power to show that tenecteplase is non-inferior to alteplase, we will need 759 subjects in each arm of the trial. The choice of 5% as a non-inferiority margin represents 50% of the estimate of effect size (10%) for intravenous alteplase administered within 3 hours of stroke symptom onset vs. control for the outcome mRS 0-1 measured at 90 days. This data from Emberson et al is the largest patient level
pooling of data from all intravenous alteplase vs. control trials to date.\(^2\) The choice of 5% as the non-inferiority margin in this trial means that at least half of the point estimate of effect for intravenous alteplase vs. control will be preserved. Additionally, the choice of 5% is strictly less than the lower CI bound of ~6% on the same point estimate in data from Emberson et al.\(^2\) Hence the non-inferiority margin is guaranteed to be less than the lowest reasonable estimate of alteplase vs. control (placebo) effect size.

As always with non-inferiority designs, the 5% non-inferiority margin is the lower boundary on the 95% confidence interval surrounding the point estimate obtained from the proposed trial.\(^3\) As a specific example, if the rate of excellent functional outcome in the alteplase group is actually 35% as postulated, the worst corresponding rate in the TNK group which will meet the non-inferiority test is 34.7%, for which the lower confidence bound on the difference is -4.96%. In the ESCAPE trial that we led, loss to follow-up for primary outcome was 1.3%.\(^3\) Similar rates are seen in the ongoing trials that we lead (ESCAPE NA 1 and TEMPO 2 trials; approximately 2 to 4%). We therefore estimate a loss to follow-up rate <5%, thus resulting in a sample size of 1600 subjects.

Missing data rate in the QuICR registry in 2017 was <5% for all data fields. The OPTIMISE registry is achieving similar metrics in 2018. Data linkages with administrative data sources and central telephone assessment of primary outcome by trial personnel in coordination with registry personnel will also ensure that loss to follow-up is minimal.

6.2 The planned recruitment rate

Data from the QuICR registry (years 2016 - 2018) suggests that 550 to 600 patients with acute ischemic stroke receive thrombolysis every year within Alberta. The proposed trial has pragmatic eligibility criteria; any patient who is eligible for thrombolysis as per current guidelines and treating physician discretion is eligible for recruitment into the trial. Trial recruitment will use the existing registry infrastructure and processes to recruit subjects into the trial. Quick and easy randomization will be readily available to frontline physicians and allied health personnel at the emergency room. Information about the trial will be repeatedly reinforced as part of the QuICR and OPTIMISE registries’ ongoing quality improvement collaborative (see attached letters of support from both registries). Although ideally, we would like to enroll every eligible patient in the trial, after accounting for other ongoing acute stroke trials and being pragmatic about potential difficulties in trial enrollment early on, we will target at least 50% of all current thrombolysis eligible patients for recruitment in the first year at each enrolling site. This would mean approximately 300 subjects recruited in the first year into the trial from sites participating in the QuICR. OPTIMISE sites will also be participating. These sites average over 1200 thrombolysis cases per year in total, so again if conservatively, only 50% of all current thrombolysis eligible patients are recruited in the first year, this would mean 600 patients per year once all sites are running. Even if only half the sites in both registries are actively enrolling in the first year, this would still allow us to recruit at least 450 patients in the first year and 600 or more patients from year two onwards. Between the QuICR and OPTIMISE sites therefore, even accounting for variability in site initiation, contracts and REB approvals, we expect to be able to complete enrollment in 3 years.

6.3 Participant Compliance Monitoring
Because the treatment is a one-time dose of an intravenous thrombolytic agent, given immediately after randomization, no problems with compliance are anticipated in the trial.

6.4 Rate of loss to follow up and Missing data

We are estimating a loss to follow up rate of < 5%. Central assessment of primary outcome by trial personnel in co-ordination with registry personnel will ensure that loss to follow-up is minimal. In the ESCAPE trial, loss to follow-up was 1.3%. Similar rates are seen in the ongoing trials that we lead (ESCAPE NA 1 and TEMPO 2). Sensitivity analyses using various imputation techniques (worst case, best case, multiple imputation, hot-decking and nearest neighbor) will be specified prospectively in the Statistical Analysis Plan (SAP) if more than 5% of patients randomized are missing the primary endpoint.

6.5 Centers involved

The QuiCR registry currently includes 15 Primary Stroke Centers that provide thrombolysis treatment only, and 2 Comprehensive Stroke Centers that provide both thrombolysis treatment and endovascular treatment. OPTIMISE registry sites will also be participating. AllQuiCR and OPTIMISE sites, as well as additional sites, will be eligible to participate in this study if they a) are actively participating or agree to participate in one of the two registries or b) have regular institutional reporting/contribution of data to administrative datasets (e.g. Discharge Abstract Database) that can be accessed and linked to trial outcomes as per statistical analysis plan, and c) obtain local REB/IRB approval.

6.6 Proposed types of analyses

Primary efficacy analysis will be intention to treat. Given pragmatic eligibility criteria and up-front one-time treatment, we expect no cross-overs and very few protocol violations. A protected hierarchical analysis plan will be performed. First, non-inferiority will be established if the lower boundary of the 95% confidence interval of the % difference in subjects achieving good outcome (mRS 0-1) in the tenecteplase versus the alteplase arm is greater than – 5% (the non-inferiority margin). If non-inferiority is demonstrated, then a test of superiority will be performed as part of secondary analysis. The primary analysis for efficacy will be a stratified Cochran-Mantel-Haenszel (CMH) test where registry (QuiCR vs. OPTIMISE) will be used as a stratification variable. If non-inferiority is not demonstrated, all subsequent analyses will be considered hypothesis-generating. As sensitivity analysis, logistic regression will be used to provide an adjusted estimate of effect size of the effectiveness of tenecteplase over alteplase. The odds ratio of good 90-day outcome associated with the treatment groups will be estimated using a logistic regression model after adjusting for registry, age, sex, baseline stroke severity and onset-to-needle time. For secondary analyses, frequency tables will be used to summarize binary variables by treatment group. Descriptive statistics will be used to summarize continuous data variables by treatment group. Similar to the primary efficacy variable, binary secondary outcomes will be analyzed using logistic regression analysis. The continuous secondary outcomes will be analyzed using analysis of covariance (ANCOVA) and mixed-effects regression with the registry (QuiCR vs. OPTIMISE) variable treated as a random-effect. If non-inferiority of the primary outcome is demonstrated, a hierarchical multiplicity
adjustment will be used to determine the Type I error for testing the secondary outcomes in order to control the overall familywise Type I error rate for the study. Sex will be a unit of analysis. In addition, given previous literature suggesting underutilization of thrombolysis in females, sex-based differences in recruitment, workflow and processes and outcomes will constitute important pre-specified subgroup analyses. Details will be provided in the statistical analysis plan that will be developed and reviewed by the trial steering committee.

6.7 Proposed frequency of analyses

Schedule for interim analyses (at every 1/3rd of total patients enrolled; see Table) will be finalized in consultation with the DSMC. The overall principle of interim analyses will be to determine early if tenecteplase causes more mortality OR is significantly inferior than alteplase at interim. The safety stopping rule pertains to a substantial mortality difference favoring alteplase at interim. This rule is met if the observed p-value for mortality comparing randomized groups is below a threshold defined using a power family approach to alpha-spending using q=1, and if the numeric rate of mortality favors alteplase (e.g., if it is found that tenecteplase is substantially and significantly inferior to alteplase in terms of mortality at interim). For inferiority, the stopping rule is defined in terms of absolute difference between the tenecteplase and alteplase rates of mRS 0-1; if at interim, the difference Δ for mRS 0-1 in the tenecteplase vs. alteplase group is lower (worse) than the indicated value, the trial will be stopped for significant inferiority of tenecteplase as it will be unlikely that the effectiveness endpoint can be met. Final analyses will be conducted on completion of the trial.

<table>
<thead>
<tr>
<th>Evaluable Sample Size</th>
<th>Stopping for Safety</th>
<th>Stopping for Futility</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Two-Sided Alpha for Mortality</td>
<td>Effect size Δ for mRS 0-1</td>
</tr>
<tr>
<td>533 (one-third)</td>
<td>0.0167</td>
<td>-10.0%</td>
</tr>
<tr>
<td>1067 (two-thirds)</td>
<td>0.0218</td>
<td>-5.0%</td>
</tr>
<tr>
<td>1600 (final)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

6.8 Pre-specified subgroup analyses

Subgroup analyses will be performed by registry (QuICR vs. OPTIMISE), type of enrolling hospital (PSCs vs. CSCs), age (continuous and as < 80 years vs. >= 80 years), sex and baseline stroke severity (NIHSS; < 8, 8-15 and > 15). Subgroup analyses will help to determine if there is overwhelming efficacy or futility in any pre-specified subgroup. Subgroup analyses will remain exploratory.

7. Trial Management

7.1 Arrangements for day-to-day management of the trial

The study will be managed by the Act/OPTIMISE Trial Management committee and will be overseen by the QuICR and OPTIMISE executives. The trial will also have a co-ordinator who will be responsible for the day-to-day management of the trial. The co-ordinator will work closely with the QuICR and OPTIMISE registry personnel to conduct regular trial quality improvement initiatives and to ensure blinded assessment of outcomes. The Clinical Research Unit (CRU) at the University of Calgary and another data management vendor will develop the trial database and Randomization tool.
the data management vendor will host the trial database and randomization tool. Subject data will be captured and managed by study sites on a Web-based electronic data capture tool (eCRF) configured by the sponsor and hosted by the electronic data capture vendor. Interpretation of results, manuscript submission for publication, and presentation of results at national and international conferences, will be performed by the Trial Executive.

7.2 Data Confidentiality

The QuICR registry data is entered by registry/Alberta Health Service (AHS) personnel in a secure database at the Clinical Research Unit (CRU) of the University of Calgary. The QuICR registry is operating under a legal agreement (Information Management Agreement –IMA) with AHS, such that the University of Calgary is acting as a manager of identifiable health information for Alberta Health Services. The custodian of the data is the Alberta Health Services. The Alberta Health Service has completed a Privacy Impact Assessment for the QuICR Registry through the Office of the Information and Privacy Commissioner of Alberta that protects confidentiality of data.

OPTIMISE is managed by the Canadian Stroke Consortium. OPTIMISE registry data is entered by site personnel using a simple web-based electronic case report form, held in a REDCap database and stored on a secure server at the Population Health Research Institute at McMaster University. Data entry is handled at each site and quality assurance processes managed at the central data management site. Patient identifiers are not collected centrally. Each patient is assigned a unique OPTIMISE ID #; sites maintain patient logs that link patient identifiers to the unique OPTIMISE ID # in a secure platform.

The electronic data capture vendor will maintain a secure trial database that will link study subject ID with the registry ID. This database will also record SAEs occurring within 24 hours, 90-120 day outcomes and patient contact information. The registry ID in this secure database will be used to link to administrative data sources (e.g. DAD). Details will be provided in the MOP.

The randomization and electronic consent applications will be maintained by the electronic data capture vendor in a secure -managed environment. Both the application and the environment will adhere to industry-standard security practices such as data encryption, regular backups, etc.

The secure final study database will have deidentified data (by Trial ID) from a) the QuICR or the OPTIMISE registry, b) the trial database, c) the electronic consent application and d) the administrative data sources. This data will be stored on password protected and encrypted computers at the University of Calgary, in a statistical program data set.

Paper records will be kept in locked file cabinets or in a secure office. Clinical information will not be released without written permission of the subject, except as necessary for monitoring by ethics committees, regulatory bodies, the sponsor, or the sponsor’s designee. All study investigators at the clinical sites must ensure that the confidentiality of personal identity and information of study participants is maintained at all times. Province specific privacy regulations where applicable, must be followed. Only properly authorized persons will have access to any records. Personal medical information is always treated as confidential.
7.3 Ethics

Where approved by the local ethics review board, to reduce time to treatment, patients will be randomized using a deferral of consent procedure. The study protocol, deferred consent documents (patient and surrogate) and any subsequent modifications will be reviewed and approved by the local ethics committee responsible for oversight of the study. Approval from the committee must be obtained before starting the study and will be documented in a letter to the Sponsor (and any Participating Site Investigators).

The deferred consent process is described in Section 5.4 and will include an e-consent process or a paper-based consent process. Where permitted, for subjects who cannot provide consent themselves, a legally authorized representative, or person with power of attorney, may sign the consent form. A copy of the consent form will be given to the subject, the legally authorized representative, or the person with power of attorney; and this fact will be documented in the subject’s clinical record. If new safety information results in significant changes in the risk/benefit assessment, the consent form should be reviewed and updated if necessary. All patients (including those already treated) will be informed of the new information.

7.4 Monitoring

The AcT trial is a pragmatic registry embedded trial testing if intravenous tenecteplase (an intravenous thrombolytic drug tested and found safe in multiple phase 2 and one phase 3 trial is patients with acute ischemic stroke) can replace intravenous alteplase (the current standard care) in patients who are otherwise eligible to receive the latter in routine care. The emphasis in trial execution will therefore be on making sure that the “right” patient receives the appropriate intervention (i.e., correct randomization, treatment assignment) with adequate assessment of primary outcome (i.e., complete, correct, and timely blinded event ascertainment).

To align the requirements of good clinical practice with the considerations in a pragmatic randomized clinical trial, a risk-based approach to monitoring will be used. The registries will use their existing infrastructure and mandate to focus on quality patient care. Central monitoring will be the focus with limited on-site risk-based monitoring (if required) in co-ordination with the registry coordinators.

The following steps will be in place and monitored:

1. Randomization: The randomization module is built by the CRU at the University of Calgary and the electronic data capture vendor. The module and the mechanisms to maintain allocation concealment throughout the trial will be written down, signed by the sponsor and the electronic data capture vendor will be available for assessment. The randomization module will be tested at a frequency determined by the electronic data capture vendor current quality control practices to ensure that the above requirements are met.

2. Consent: Where approved by the local ethics review board, to reduce time to treatment, patients will be randomized using a deferral of consent procedure. Sites will receive a check list and automated emails from the sponsor reminding them to obtain consent. Upon request, the
electronic data capture vendor shall make available detailed consent information, including patient signatures to authorized study personnel. Sites will document in a checklist (see section 5.3 above) if consent has been obtained, from whom and reasons if consent could not be obtained. If consent could not be obtained in spite of best efforts (no surrogate or surrogate cannot be contacted), the patient will continue in the trial. Where approved by local ethics committees and if electronic consent was not possible, the last page of the signed paper consent form for each subject will be sent for central review.

With the exception of patients who died within 7 days or who are unable to provide consent and do not have any legal representatives, sites are expected to obtain consent within 7 days of subject enrolment or before discharge, whichever is earlier. In subjects who die, and consent has yet to be obtained, sites are expected to make reasonable efforts to obtain consent from legal representatives. A letter of bereavement may be provided to sites to send to the next of kin that provides information on the patient’s enrolment. If subjects or, if incapacitated, their legal representatives, withdraw from further participation (including long-term follow-up by record linkage), sites will inform the sponsor about this within 7 days of this happening. Subjects may withdraw consent for further contact but continue follow-up via record linkage. In the event that consent is withdrawn, data collected up until the point of withdrawal will be used for analysis. The site will update the patient consent log and inform the sponsor of the same.

3. Conduct of the trial: This trial is a pragmatic randomized controlled trial embedded within registries (QuICR and OPTIMISE) that are focused on improving quality of health care delivery in patients receiving acute stroke treatments such as thrombolysis and EVT. The sponsor will therefore help support the efforts of the registries in educating and implementing best clinical practices in all participating sites.

Delegation Logs: The site qualified investigator (QI) will have primary responsibility for screening and enrolling patients within the trial. The site QI will, along with the sponsor, inform and train local qualified physicians and co-ordinators to screen, randomize and administer allocated drug. A delegation of authority log will document the personnel who have completed this training and can enrol patients into the trial. The delegation log will also document key trial-specific tasks that may be delegated to other members of the team, including site co-ordinators. Assessment of primary outcome is done centrally using phone call and is the sponsor’s responsibility. The sponsor will keep a delegation log of personnel trained in this task.

Training Logs: Through sponsor-initiated study start up meetings, site QI initiated meetings or through emails/webinars, local qualified physicians treating acute stroke patients as per routine care and site co-ordinators will be informed and trained to screen, randomize and administer allocated drug (as described in the Delegation of Authority Log section above). A training log for these training sessions will be maintained. We will require all randomizing investigators and site co-ordinators to undertake an online training procedure for the trial. This training will be required prior to activation of an individual’s randomizer access. We will log their successful training centrally and will provide sites with lists of trained personnel. In addition, the sponsor will periodically provide the sites with posters, checklists and other educational material to help
with the conduct of the trial. Finally, the sponsor will train personnel centrally for assessment of 90-120 day outcome. A training log for the above sessions will be maintained centrally.

Documentation to support qualification of individuals: The Qualified Investigator at the site, and the site lead research co-ordinator CV’s and documentation supporting current training in GCP and Health Canada Division 5 will be collected.

Since physicians administering intravenous thrombolysis to patients with acute stroke are qualified to do so as part of routine standard of care, the site QI will ensure that physicians enrolling patients continue to remain qualified to screen and treat acute stroke patients annually. This will be done by ensuring that all physicians with randomizer access continue to be actively licensed to practice medicine in their jurisdiction (e.g. CPSO, CPSA) by collecting annual printouts from those regulatory bodies confirming their active license.

4. Interventions: The trial will capture if a) the correct drug b) the correct dose was administered c) and e) the vial LOT number and expiry date of the administered drug in the secure database maintained by the data management vendor. (see section 5.3).

5. Data linkages and flow: The data flow is designed to

a) Ensure patient confidentiality. The sponsor will not have access to the patient’s Health Care Number that could reidentify individual patients.

b) Collate all data from multiple existing data sources to develop a final de-identified trial database that only has the unique Trial ID.

To fulfil the above objectives, the data flow shown in Figure below will be followed. The Trial database is developed by the Clinical Research Unit (CRU) at the University of Calgary and maintained by another data management vendor. …

Each subject enrolled in the trial gets a unique Trial ID. The Trial ID is stored in the secure Trial Database. Each patient in the QuICR or OPTIMISE registries also has a registry identifier (herewith called Registry ID). The sites will enter the Registry ID in the secure Trial Database. An automated email from a secure server will go to the site reminding them to enter the Registry ID into the Trial Database. The sponsor will be able to check if the Registry ID is entered into the Trial Database but will not have “read access” to individual Registry IDs.

The designated Alberta Health Service analyst for QuICR (privacy assessed) and the site co-ordinators for OPTIMISE trial sites have access to the Registry ID and patient Health Care Numbers. Through their “read access” of the Trial ID and the Registry ID in the trial database, they will be able to then provide the Trial ID and the linked Health Care Numbers to the Canadian Institute for Health Information (CIHI).

CIHI and the QuICR and OPTIMISE registries will all then provide data labelled with the Trial ID only back to the sponsors. This final database with Trial ID as the only identifier will be the data available to the Investigators for analysis. Quality of the data linkages will be ascertained by qualified personnel with expertise in health service data linkages.
Figure showing data workflow within the AcT Trial.

# SAE, Serious Adverse Events; CIHI, Canadian Institute for Health Information; DAD, Discharge Abstract Database.
6. Blinded Primary Outcome Assessment: A blinded assessor trained in administering the Rankin Focused Assessment method and DQ-5D-5L will perform the 90 to 120-day outcome assessments. The definition of a blinded assessor is that they are blinded to the treatment allocation and not involved in the patient’s care. This person will sign a form that attests to the blinding as described above for performing all outcome assessments. Protocol deviations will be reported for any 90-120-day assessments that were performed by an “unblinded” assessor. Every effort will be made to collect an outcome assessment on each subject and have minimal “lost to follow-up assessments”. Occasionally, the local site staff may be requested to contact the subject for this information...Cognitive assessments will be completed directly by consenting participants using an online, automated assessment platform, with login via Trial ID only, so no bias is possible and identifiable data will not be captured.

7. Safety data: Details on mechanisms to be utilized in the trial to collect safety data and data on AEs is described in section 5.11. The sponsor will work the sites and the registries to ensure that all secondary and safety outcomes for the trial that are available through the registries (see Section 5.9) are entered within 90 days of subject enrolment.

8. Change in Study Personnel: When there are any changes to study personnel during the trial, it is the site’s responsibility to notify the sponsor. Personnel who are no longer active at the site will be assigned an “inactive status” and their data privileges modified appropriately. The sponsor will maintain a log of any and all such changes. In co-ordination with the site co-ordinator, the sponsor will ensure access to all trial specific educational material to any new study personnel listed by the site.

7.5 Study Documentation and Record Keeping

7.5.1 Retention of Documents
The sponsor and the participating site investigators should maintain appropriate records as described in the protocol. At the site level, this will include the study protocol and any amendments, ethics correspondence and approval, patient log with a duly filled in checklist, a copy of the patient enrolment form and patient or surrogate consent forms (see section 5.3) They will also maintain their part of the trial database. At the sponsor/central level, this will include the study protocol and any amendments, ethics approval documents from sites, trial database along with the last page of the signed consent forms, copies of any communication with Health Canada and site initiation and training logs including logs of all educational efforts described in section 7.4. Any or all of these files may be stored electronically. The sponsor (and any participating site investigators) must keep these documents on file for 25 years after completion or discontinuation of the study or as deemed by data sources such as CIHI After that period of time the documents may be destroyed, subject to local regulations.

7.5.2 Source Documents
Any participating site investigators shall supply the sponsor on request with any required data from the study documentation or clinic records. In case of special problems and/or governmental
queries or requests for audit inspections, it is also necessary to have access to the complete study
records, provided that patient confidentiality is protected.

7.5.3 Inspections
The sponsor understands that documents for this trial should be made available to appropriately
qualified personnel or to health authority inspectors after appropriate notification.

7.6 Data Safety Monitoring Committee
The independent Data Safety and Monitoring Committee (DSMC) will be constituted in consultation
with the steering committee and include clinicians, a nurse representative, a statistician and a patient
representative. The DSMC will meet by teleconference to review safety data after each cohort of
approximately 500 participants is enrolled. To prevent bias at the trial and investigator level, all
interim results on safety will only be available to the DSMC. Stopping rules based on safety alone
will be specified in the DSMC charter. Mechanisms to ensure this will be detailed in the DSMC
Charter. The Data Safety and Monitoring Committee will be constituted based on the DAMOCLES
charter format. The DSMC will meet by teleconference to review safety data after each 1/3rd cohort of
subjects are enrolled.

7.7 End of trial
End of trial is defined as when data on the last patient recruited into the trial is completed. The trial
will end when the trial steering committee agrees that one or more of the following situations applies:

1. The planned sample size has been achieved
2. The DSMC advises discontinuation because of safety concerns
3. New information makes it inappropriate to continue to randomise patients to one or other arm
   of the trial
4. Recruitment is so poor that completion of the trial is considered difficult

7.8 Ancillary Studies, Co-Enrollment and Publication Policy
The trial steering committee will constitute a publication committee that will include site principal
investigators and the lead statistician. Policies will be detailed in a Publication Policy Charter.
Ancillary studies will also be vetted by the trial steering committee and a decision made on merits of
the proposed study.

Patients enrolled in the AcT RRCT are eligible to be enrolled into the EASI-TOC RCT. This study
targets a subgroup of patients with ischemic stroke who have what are called tandem occlusions.
EASI-TOC aims to determine whether, in addition to thrombectomy to recanalize intracranial
occlusion (standard of care); patients with a tandem occlusion should also be acutely treated with a
stent to revascularize their cervical internal carotid artery during the thrombectomy procedure.
Inclusion in the AcT and EASI-TOC trials do not subject patients to increased risk. No multiplicative
biological interaction between the interventions studied in both studies is expected. Patients are
randomized just before or at the start of the thrombectomy procedure, once the carotid lesion is

Version 2.0

confirmed by angiography. The allocation is 1:1 (stent versus no stent). Both approaches lesion is confirmed by angiography. The allocation is 1:1 (stent versus no stent). Both approaches used in EASI-TOC are considered standard care and used in daily clinical practice. Neither approach is therefore experimental. The pragmatic design of the two studies prevents patients from being subjected to additional study specific investigations, procedures or clinical follow-up beyond usual care.

It is estimated that <5% of patients eligible for enrolment into the AcT RRCT will also be candidates for EASI-TOC (approximately 60-80 patients out of a planned 1600 patients to be included in AcT). Approximately 1/3rd of subjects eligible for AcT will likely undergo endovascular thrombectomy i.e. 533 subjects.

Statistical simulations with different possible interaction scenarios suggest limited effect on outcomes within both studies. Outcome ascertainment in EASI-TOC does not influence or affect outcome ascertainment in AcT. There are precedents in medicine for including patients in more than one randomized trial, especially in the fields of oncology and critical care and more recently with COVID-19.

On request, the trial steering committee will follow the same processes above to determine if co-enrolment will be allowed for other trials. The process will involve consultation with statisticians, ethics boards, patient focus groups and with Health Canada.

7.9 Data sharing plan

The Trial Steering Committee will follow the CIHR guidelines on public access to trial results. Upon completion of trial, a public use database will be prepared by stripping any and all personal identifiers. The data files will be distributed along with the data dictionary and a brief instruction (“Readme”) file. These data files will be made available to the public only after all major manuscripts (including secondary analysis papers) of the trial are accepted for publication.

8. References


Version 2.0

39

**APPENDIX**

**Table 1:** List of Adverse Events. *(Stroke. 2014; 45: 2677-2682)*

<table>
<thead>
<tr>
<th>Adverse Event (AE)</th>
<th>Incidence (AEs)</th>
<th>Serious Adverse Event (SAE)</th>
<th>Incidence (AEs)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Version 2.0 40
<table>
<thead>
<tr>
<th>Condition</th>
<th>1,000 patients)</th>
<th>Condition</th>
<th>1,000 patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyrexia</td>
<td>160.69</td>
<td>Stroke in Evolution</td>
<td>11.2</td>
</tr>
<tr>
<td>Headache</td>
<td>137.32</td>
<td>Pneumonia</td>
<td>16.8</td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td>87.45</td>
<td>Ischemic Cerebral Infarction</td>
<td>21.7</td>
</tr>
<tr>
<td>Anxiety</td>
<td>90.04</td>
<td>Brain Edema</td>
<td>26.0</td>
</tr>
<tr>
<td>Constipation</td>
<td>88.48</td>
<td>Cardiac Failure</td>
<td>29.4</td>
</tr>
<tr>
<td>Hypertension</td>
<td>75.67</td>
<td>Myocardial Infarction</td>
<td>32.3</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>65.63</td>
<td>Cerebral Hemorrhage</td>
<td>34.8</td>
</tr>
<tr>
<td>Nausea</td>
<td>68.92</td>
<td>Aspiration Pneumonia</td>
<td>37.3</td>
</tr>
<tr>
<td>Vomiting</td>
<td>67.88</td>
<td>Respiratory Failure</td>
<td>39.5</td>
</tr>
<tr>
<td>Stroke in Evolution</td>
<td>60.95</td>
<td>Hemorrhagic Transformation</td>
<td>41.7</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>57.32</td>
<td>Pulmonary Embolism</td>
<td>43.7</td>
</tr>
<tr>
<td>Atrial Fibrillation</td>
<td>52.81</td>
<td>Atrial Fibrillation</td>
<td>45.5</td>
</tr>
<tr>
<td>Depression</td>
<td>44.16</td>
<td>Urinary Tract Infection</td>
<td>47.2</td>
</tr>
<tr>
<td>Somnolence</td>
<td>32.38</td>
<td>Pulmonary Edema</td>
<td>48.7</td>
</tr>
<tr>
<td>Insomnia</td>
<td>39.31</td>
<td>Cerebrovascular Disorder</td>
<td>50.2</td>
</tr>
<tr>
<td>Cardiac Failure</td>
<td>33.94</td>
<td>Cardiac Arrest</td>
<td>51.7</td>
</tr>
<tr>
<td>Hypotension</td>
<td>36.36</td>
<td>Carotid Artery Disease</td>
<td>53.1</td>
</tr>
<tr>
<td>Hematuria</td>
<td>35.15</td>
<td>Sepsis</td>
<td>54.3</td>
</tr>
<tr>
<td>Brain Edema</td>
<td>30.13</td>
<td>Angina Pectoris</td>
<td>55.5</td>
</tr>
<tr>
<td>Pain</td>
<td>25.97</td>
<td>Hypotension</td>
<td>56.6</td>
</tr>
<tr>
<td>Hemorrhagic Transformation</td>
<td>28.92</td>
<td>Coma</td>
<td>57.7</td>
</tr>
<tr>
<td>Edema Peripheral</td>
<td>25.80</td>
<td>Pyrexia</td>
<td>58.8</td>
</tr>
<tr>
<td>Bradycardia</td>
<td>30.48</td>
<td>Renal Failure</td>
<td>59.8</td>
</tr>
<tr>
<td>Ecchymosis</td>
<td>25.97</td>
<td>Headache</td>
<td>60.7</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>29.61</td>
<td>ICP increased</td>
<td>61.6</td>
</tr>
<tr>
<td>Ischemic Cerebral Infarction</td>
<td>28.57</td>
<td>Respiratory Tract Infection</td>
<td>62.5</td>
</tr>
<tr>
<td>Cerebral Hemorrhage</td>
<td>24.59</td>
<td>Bradycardia</td>
<td>63.3</td>
</tr>
<tr>
<td>Angina Pectoris</td>
<td>26.32</td>
<td>Transient Ischemic Attack</td>
<td>64.1</td>
</tr>
<tr>
<td>Aspiration Pneumonia</td>
<td>24.76</td>
<td>Gastrointestinal Hemorrhage</td>
<td>64.9</td>
</tr>
<tr>
<td>Cough</td>
<td>23.72</td>
<td>Hypertension</td>
<td>65.6</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>24.94</td>
<td>Hemorrhagic Cerebral Infarction</td>
<td>66.3</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>24.76</td>
<td>Somnolence</td>
<td>67.1</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>24.24</td>
<td>Cerebral Incarceration</td>
<td>67.6</td>
</tr>
<tr>
<td>Musculoskeletal Pain</td>
<td>23.72</td>
<td>Deep Vein Thrombosis</td>
<td>68.2</td>
</tr>
<tr>
<td>Back Pain</td>
<td>24.07</td>
<td>Syncope</td>
<td>68.8</td>
</tr>
<tr>
<td>Confusional State</td>
<td>20.61</td>
<td>Depression</td>
<td>69.3</td>
</tr>
<tr>
<td>Respiratory Tract Infection</td>
<td>19.05</td>
<td>Hematuria</td>
<td>69.7</td>
</tr>
<tr>
<td>Rash</td>
<td>18.18</td>
<td>Vomiting</td>
<td>70.2</td>
</tr>
<tr>
<td>Purpura</td>
<td>11.77</td>
<td>Cerebrovascular Accident</td>
<td>70.6</td>
</tr>
<tr>
<td>Condition</td>
<td>Score</td>
<td>Diagnosis</td>
<td>Score</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------</td>
<td>-------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Pulmonary Edema</td>
<td>17.66</td>
<td>Convulsion</td>
<td>71.0</td>
</tr>
<tr>
<td>Urinary Incontinence</td>
<td>13.16</td>
<td>COPD</td>
<td>71.4</td>
</tr>
<tr>
<td>Myocardial Infarction</td>
<td>16.80</td>
<td>Dyspnea</td>
<td>71.8</td>
</tr>
<tr>
<td>Respiratory Failure</td>
<td>15.24</td>
<td>Anemia</td>
<td>72.2</td>
</tr>
<tr>
<td>Anemia</td>
<td>14.72</td>
<td>Aspiration</td>
<td>72.5</td>
</tr>
<tr>
<td>Abdominal Tenderness</td>
<td>17.49</td>
<td>Bronchitis Acute</td>
<td>72.9</td>
</tr>
<tr>
<td>Rhonchi</td>
<td>12.64</td>
<td>Cardiopulmonary Failure</td>
<td>73.2</td>
</tr>
<tr>
<td>Lung Crepitation</td>
<td>12.47</td>
<td>Constipation</td>
<td>73.6</td>
</tr>
<tr>
<td>Extrasystoles</td>
<td>13.16</td>
<td>Epilepsy</td>
<td>73.9</td>
</tr>
<tr>
<td>Restlessness</td>
<td>16.10</td>
<td>Abdominal Tenderness</td>
<td>74.2</td>
</tr>
<tr>
<td>Bronchitis Acute</td>
<td>14.89</td>
<td>Dehydration</td>
<td>74.6</td>
</tr>
<tr>
<td>Pulmonary Congestion</td>
<td>11.77</td>
<td>Ileus</td>
<td>74.9</td>
</tr>
<tr>
<td>Urinary Retention</td>
<td>13.51</td>
<td>Septic Shock</td>
<td>75.2</td>
</tr>
<tr>
<td>Renal Failure</td>
<td>12.29</td>
<td>Colon Neoplasm</td>
<td>75.5</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>11.43</td>
<td>Rectal Hemorrhage</td>
<td>75.8</td>
</tr>
<tr>
<td>Carotid Artery Disease</td>
<td>11.43</td>
<td>Tachycardia</td>
<td>76.1</td>
</tr>
<tr>
<td>Dizziness</td>
<td>12.81</td>
<td>Thrombosis</td>
<td>76.4</td>
</tr>
<tr>
<td>Phlebitis</td>
<td>12.47</td>
<td>Ventricular Tachycardia</td>
<td>76.7</td>
</tr>
<tr>
<td>Edema</td>
<td>11.77</td>
<td>Arrhythmia</td>
<td>76.9</td>
</tr>
<tr>
<td>Accident and/or Injury</td>
<td>7.45</td>
<td>Coronary Artery Disease</td>
<td>77.2</td>
</tr>
<tr>
<td>Hematoma</td>
<td>11.77</td>
<td>Multi-organ Failure</td>
<td>77.4</td>
</tr>
<tr>
<td>Erythema</td>
<td>12.47</td>
<td>Neurological Symptom</td>
<td>77.7</td>
</tr>
<tr>
<td>Sleep Disorder</td>
<td>10.91</td>
<td>Respiratory Arrest</td>
<td>77.9</td>
</tr>
<tr>
<td>Pulmonary Embolism</td>
<td>10.91</td>
<td>Shock</td>
<td>78.2</td>
</tr>
<tr>
<td>Ventricular Tachycardia</td>
<td>11.60</td>
<td>Urosepsis</td>
<td>78.5</td>
</tr>
<tr>
<td>Cerebrovascular Disorder</td>
<td>6.75</td>
<td>Cardiogenic Shock</td>
<td>78.7</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
<td>11.26</td>
<td>Hip Fracture</td>
<td>78.9</td>
</tr>
<tr>
<td>Bronchospasm</td>
<td>9.52</td>
<td>Melena</td>
<td>79.1</td>
</tr>
<tr>
<td>Body Temperature Increased</td>
<td>11.60</td>
<td>Nausea</td>
<td>79.4</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>8.48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Convulsion</td>
<td>9.52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain in Extremity</td>
<td>10.74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coma</td>
<td>7.62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweating Increased</td>
<td>9.52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sepsis</td>
<td>8.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breath Sounds Decreased</td>
<td>7.62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>8.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine Output Decreased</td>
<td>9.35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leucocytosis</td>
<td>6.58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apnea</td>
<td>9.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac Arrest</td>
<td>8.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syncope</td>
<td>9.18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemorrhagic Cerebral</td>
<td>7.79</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Version 2.0  
<table>
<thead>
<tr>
<th>Condition</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infarction</td>
<td></td>
</tr>
<tr>
<td>Pleural Effusion</td>
<td>7.27</td>
</tr>
<tr>
<td>Fatigue</td>
<td>9.00</td>
</tr>
<tr>
<td>Neck Pain</td>
<td>8.66</td>
</tr>
<tr>
<td>Rash Erythematous</td>
<td>5.71</td>
</tr>
<tr>
<td>Hyponatremia</td>
<td>8.48</td>
</tr>
<tr>
<td>Shoulder Pain</td>
<td>7.79</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>7.45</td>
</tr>
<tr>
<td>Dehydration</td>
<td>6.93</td>
</tr>
<tr>
<td>Procedural Complication</td>
<td>7.62</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>7.97</td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>6.93</td>
</tr>
<tr>
<td>Edema Legs</td>
<td>6.23</td>
</tr>
<tr>
<td>Fecal Incontinence</td>
<td>6.93</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>5.89</td>
</tr>
<tr>
<td>Hiccups</td>
<td>6.41</td>
</tr>
<tr>
<td>Neurological Symptom</td>
<td>6.23</td>
</tr>
<tr>
<td>Lung Disorder</td>
<td>5.54</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>7.45</td>
</tr>
<tr>
<td>Decubitus Ulcer</td>
<td>7.27</td>
</tr>
<tr>
<td>Sick Sinus Syndrome</td>
<td>6.06</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>6.06</td>
</tr>
<tr>
<td>Gastrointestinal Hemorrhage</td>
<td>6.23</td>
</tr>
<tr>
<td>Infusion Site Reaction</td>
<td>6.41</td>
</tr>
<tr>
<td>Hypocalcemia</td>
<td>6.06</td>
</tr>
<tr>
<td>Epigastric Pain</td>
<td>5.54</td>
</tr>
<tr>
<td>Muscle Spasms</td>
<td>6.41</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>6.23</td>
</tr>
<tr>
<td>Supraventricular</td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>5.89</td>
</tr>
<tr>
<td>Deep Vein Thrombosis</td>
<td>5.54</td>
</tr>
<tr>
<td>Candidiasis</td>
<td>4.68</td>
</tr>
<tr>
<td>Atrial Flutter</td>
<td>5.54</td>
</tr>
<tr>
<td>ICP Increased</td>
<td>6.06</td>
</tr>
<tr>
<td>Transient Ischemic Attack</td>
<td>5.19</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>5.71</td>
</tr>
<tr>
<td>Atelectasis</td>
<td>4.50</td>
</tr>
<tr>
<td>Wheezing</td>
<td>5.89</td>
</tr>
<tr>
<td>Melena</td>
<td>3.98</td>
</tr>
<tr>
<td>Hyperthermia</td>
<td>4.85</td>
</tr>
<tr>
<td>Hepatic Enzyme Increased</td>
<td>5.19</td>
</tr>
<tr>
<td>Fall</td>
<td>5.71</td>
</tr>
<tr>
<td>Protein C Increased</td>
<td>5.54</td>
</tr>
<tr>
<td>Condition</td>
<td>Rate</td>
</tr>
<tr>
<td>----------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Injection Site Reaction</td>
<td>3.64</td>
</tr>
<tr>
<td>ALT Increased</td>
<td>4.50</td>
</tr>
<tr>
<td>Speech Disorder</td>
<td>3.29</td>
</tr>
<tr>
<td>COPD</td>
<td>4.16</td>
</tr>
<tr>
<td>Sensory Disturbance</td>
<td>4.16</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>4.85</td>
</tr>
<tr>
<td>Bacterial Infection</td>
<td>3.46</td>
</tr>
<tr>
<td>Oral Candidiasis</td>
<td>4.68</td>
</tr>
<tr>
<td>Excoriation</td>
<td>4.33</td>
</tr>
</tbody>
</table>

ICP indicates intracranial pressure; COPD: chronic obstructive pulmonary disease; ALT: alanine transaminase.

Underlined SAEs are events not found on the original adverse event list. ICP indicates intracranial pressure; COPD: chronic obstructive pulmonary disease.

**Table 2:** Summary Characteristics of the 4 phase II trials and the one phase III trial to date comparing intravenous tenecteplase to intravenous alteplase in patients with acute ischemic stroke
<table>
<thead>
<tr>
<th>Countries</th>
<th>TNK-S2B</th>
<th>Australian TNK</th>
<th>ATTEST</th>
<th>Nor-Test</th>
<th>EXTEND-IA TNK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of sites</td>
<td>10</td>
<td>3</td>
<td>1</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Patients, n</td>
<td>112</td>
<td>75</td>
<td>96</td>
<td>1100</td>
<td>202</td>
</tr>
<tr>
<td>TNK Dose(s)</td>
<td>0.1 mg/kg</td>
<td>0.25 mg/kg</td>
<td>0.25 mg/kg</td>
<td>0.4 mg/kg</td>
<td>0.25 mg/kg</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>69.1 (16.6)</td>
<td>70 (8.23)</td>
<td>71 (12.5)</td>
<td>71 (13.8)</td>
<td>71.1 (14.4)</td>
</tr>
<tr>
<td>Sex, male</td>
<td>58 (51.8%)</td>
<td>39 (52%)</td>
<td>30.5 (31.8%)</td>
<td>660 (60%)</td>
<td>110 (54.5%)</td>
</tr>
<tr>
<td>Severity (NIHSS), mean (SD) or median (IQR)</td>
<td>TNK 0.1: 8 (5-11)</td>
<td>14.4 (2.3)</td>
<td>TNK: 12 (9-18)</td>
<td>ALT: 11 (8-16)</td>
<td>TNK: 17 (12-22)</td>
</tr>
<tr>
<td>Permitted time window</td>
<td>≤ 3h</td>
<td>≤ 6h</td>
<td>≤ 4.5h</td>
<td>≤ 4.5h</td>
<td>≤ 4.5h</td>
</tr>
<tr>
<td>Onset to treatment, mins, median (IQR) or mean (SD)</td>
<td>--</td>
<td>176 (48)</td>
<td>188 (44.5)</td>
<td>TNK: 118 (79-180)</td>
<td>TNK: 125 (102-156)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>--</td>
<td>28 (37.3%)</td>
<td>34 (35.4%)</td>
<td>119 (10.8%)</td>
<td>--</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>89 (79.5)</td>
<td>47 (62.7%)</td>
<td>48 (50%)</td>
<td>482 (43.8%)</td>
<td>--</td>
</tr>
<tr>
<td>Diabetes</td>
<td>56 (50%)</td>
<td>37 (49.3%)</td>
<td>11 (11.5%)</td>
<td>126 (11.5%)</td>
<td>--</td>
</tr>
<tr>
<td>Current smoker</td>
<td>21 (18.8%)</td>
<td>15 (20%)</td>
<td>14 (14.6%)</td>
<td>144 (13.1%)</td>
<td>--</td>
</tr>
<tr>
<td>Large vessel occlusion</td>
<td>--</td>
<td>77%</td>
<td>47%</td>
<td>--</td>
<td>100%</td>
</tr>
</tbody>
</table>

Table 3: Baseline characteristics of patients enrolled in the intravenous alteplase vs. control trials (top panel) vs. patients included in the intravenous tenecteplase vs. alteplase trials (bottom panel). Patients enrolled in the tenecteplase vs. alteplase trials had significantly less severe strokes (baseline NIHSS 6 vs. 12 on average), significantly more stroke mimics (15%), under-representation of females (40% in the TNK trials overall vs. 45% in the alteplase trials) and...
lower incidence of atrial fibrillation (14% in the tenecteplase trials vs. 24% in the alteplase trials), thus suggesting that tenecteplase vs. alteplase trial level meta-analysis does not represent well patients with acute stroke treated with intravenous alteplase.

![Webtable 1: Baseline characteristics of IST-3 and 8 previous trials, overall and separately according to time to treatment](image)

![Table 2: Key baseline characteristics of the studies included in the meta-analysis](image)

**Figure 1:** Exemplar labelling of intravenous tenecteplase and intravenous alteplase
INVESTIGATIONAL DRUG/DROGUE DE RECHERCHE

TENECTEPLASE (TNK) 50mg Vial
** DOSE 0.25mg/kg body weight**

Sponsor: University of Calgary,
Rm C1050-1403-29th St NW, Calgary, AB. T2N 2T9
ActT Trial Protocol V1.5

CAUTION: To be used by qualified investigators only/
Reservee uniquement a l’usage de chercheurs compétent

INVESTIGATIONAL DRUG/DROGUE DE RECHERCHE

ALTEPLASE (TPA) 100mg Vial
** DOSE 0.9 mg/kg body weight**

Sponsor: University of Calgary,
Rm C1050-1403-29th St NW, Calgary, AB. T2N 2T9
ActT Trial Protocol V1.5

CAUTION: To be used by qualified investigators only/
Reservee uniquement a l’usage de chercheurs compétent
Linkage rates for the QuICR Registry to Administrative Datasets

*Based on November 2018 QuICR Extract*

<table>
<thead>
<tr>
<th></th>
<th>2015/16</th>
<th>2016/17</th>
<th>2017/18</th>
<th>2018/19 Q1</th>
</tr>
</thead>
<tbody>
<tr>
<td>QuICR - DAD</td>
<td>97.7%</td>
<td>97.8%</td>
<td>96.7%</td>
<td>96.7%</td>
</tr>
<tr>
<td>QuICR – NACRS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Community stroke</td>
<td>94.3%</td>
<td>97.3%</td>
<td>96.0%</td>
<td>94.7%</td>
</tr>
<tr>
<td>presentations only</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Linkage rates depend on the quality of QuICR and administrative data. If linkage rates do not meet acceptable standards, Analytics can supply project sponsors with an account of lost records for chart review. Some examples of relevant QuICR data quality issues are provided in the following table:

<table>
<thead>
<tr>
<th></th>
<th>2015/16</th>
<th>2016/17</th>
<th>2017/18</th>
<th>2018/19 Q1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Null PHN</td>
<td>0.96%</td>
<td>0.0%</td>
<td>1.26%</td>
<td>0.55%</td>
</tr>
<tr>
<td>Invalid DOB</td>
<td>0.19%</td>
<td>0.0%</td>
<td>1.95%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

*Source: QuICR Extract as of November 2018 (VW_QUICR_EXTRACT)*
AcT trial: Statistical Analysis Plan (SAP)

<table>
<thead>
<tr>
<th>Version and Date</th>
<th>Version 1.0, 12-April-2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol Title</td>
<td>Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke: QuICR &amp; OPTIMISE Registry linked Pragmatic Randomized Controlled Trial (The AcT RRCT)</td>
</tr>
</tbody>
</table>

APPROVAL SIGNATURES

Statistician: Tolulope Sajobi

Principal Investigator: Dr. Bijoy K. Menon

April 2022

Date

April 2022

Date
1. **Introduction**

This Statistical Analysis Plan (SAP) is for the Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke (Act) Trial. Intravenous thrombolysis with alteplase is widely used in patients with acute ischemic stroke presenting early after symptom onset. Recent phase II trials have suggested that intravenous tenecteplase may be safer and potentially achieves higher early reperfusion rates than alteplase. This study investigates whether intravenous tenecteplase is non-inferior to intravenous alteplase with respect to clinical outcomes.

2. **Trial Objectives**

The Alteplase compared to Tenecteplase (Act) trial will therefore seek to demonstrate the non-inferiority of intravenous tenecteplase compared to intravenous alteplase in terms of 90-day functional outcome assessed using the modified Rankin Score. The secondary objectives of this study are to compare intravenous tenecteplase to alteplase in terms of safety and relevant secondary outcomes.

3. **Study Design**

The AcT trial is a pragmatic, registry linked, prospective, randomized (1:1) controlled, open-label parallel group clinical trial with blinded endpoint assessment of 1600 patients to test if intravenous tenecteplase (0.25 mg/kg body weight, max dose 25 mg) is non-inferior to intravenous alteplase (0.9 mg/kg body weight, max dose 90 mg) in patients with acute ischemic stroke otherwise eligible for intravenous thrombolysis as per standard care. The trial will recruit patients from the emergency departments of participating primary or comprehensive stroke centers across Canada. Study outcomes will be collected through the trial and/or through linkage to ongoing registries and national administrative databases.

4. **Randomization**

Randomization will be centralized, secure and concealed using a real-time web-based server, to prevent confounding due to allocation bias. Investigators can access the randomizer either through the internet, secure text or through a local telephone. The trial will have allocation concealment and blinded endpoint assessment. Given the pragmatic design of the trial and the time sensitive nature of acute stroke, blinding the enrolling health personnel to treatment allocation is not practical. A 1:1 randomization will be used to allocate patients to intravenous tenecteplase (0.25 mg/kg body weight, max dose 25 mg) or intravenous alteplase (0.9 mg/kg body weight, max dose 90 mg). Randomization will use a validated minimal sufficient balance (MSB) algorithm to assure balance by site.

5. **Sample size**

The primary outcome will be 90-day mRS score which will be determined by the Rankin Focused Assessment (RFA-A) method using centralized telephone interview by trained study personnel blinded to treatment allocation.

A total of 1600 subjects will be randomly assigned to receive either intravenous tenecteplase or
alteplase in a 1:1 ratio, assuming a missingness of primary outcome data/loss to follow-up rate <5%. Based on prior literature, the incidence of primary outcome (mRS 0-1) 90 days after randomization is assumed to be 38% and 35% respectively for tenecteplase vs. alteplase. Assuming a one-sided non-inferiority margin of 5%, a one-sided significance Type I error of 2.5% and 90% power to show that tenecteplase is non-inferior to alteplase, 759 subjects are needed in each arm of the trial. The choice of 5% as a non-inferiority margin represents 50% of the estimate of effect size (10%) for intravenous alteplase administered within 3 hours of stroke symptom onset vs. control for the outcome mRS 0-1 measured at 90 days obtained from the largest patient level pooled meta-analysis of such data. The choice of 5% as the non-inferiority margin in this trial means that at least half of the point estimate of effect for intravenous alteplase vs. control will be preserved. Hence the non-inferiority margin is guaranteed to be less than the lowest reasonable estimate of alteplase vs. control (placebo) effect size.

6. Interim Monitoring
Schedule for interim analyses (at every 1/3rd of total patients enrolled) will be finalized in consultation with the Data Safety Monitoring Committee (DSMC). The overall principle of interim analyses is to determine early if tenecteplase causes more mortality or is significantly inferior to alteplase at interim. Early stopping of the trial for efficacy is generally to be avoided. The guidance on stopping for safety pertains to a substantial mortality difference favoring alteplase at interim. This may be met if the observed p-value for mortality comparing the two randomized groups is below a threshold defined using a power family approach to alpha-spending using φ=1, and if the numeric rate of mortality favors alteplase (e.g., if it is found that tenecteplase is substantially and significantly inferior to alteplase in terms of mortality at interim). For inferiority of tenecteplase, the stopping may be defined in terms of absolute difference between the tenecteplase and alteplase rates of mRS 0-1 at 90-120 days. As an example, if at interim, the difference Δ for mRS 0-1 at 90-120 days in the tenecteplase vs. alteplase group is lower (worse) than an indicated value (see table in DSMC Charter for some suggested thresholds), the trial may be stopped for significant inferiority of tenecteplase. Details are provided in the Act trial DSMC charter.

7. Definition of the target populations
   7.1. Intention to Treat population
   All patients enrolled in the trial randomized on an intent-to-treat basis.

   7.2. Per-protocol population
   All patients enrolled in the trial who received any dose of study drug and met all the inclusion and exclusion criteria per current Canadian Stroke Best Practices Recommendations. Since the trial has pragmatic eligibility criteria, patients who may have been inadvertently enrolled and received thrombolysis beyond 4.5 hours from stroke onset and any treatment crossovers are defined as protocol deviations for analysis.
8. Blinding
Treatment assignment is open label. Blinding of the outcome assessment at 90-120 days will be ensured by having central personnel trained on administration of the Rankin Focused Assessment, blinded to treatment allocation, and not involved in the acute treatment period conduct the assessment via telephone.

9. Statistical Analysis
Primary analysis of the trial data to establish non-inferiority will be conducted using risk difference analysis. First, non-inferiority will be established if the lower boundary of the 95% confidence interval of the percentage difference in subjects achieving excellent outcome (mRS 0-1) in the tenecteplase versus the alteplase arm is greater than – 5% (the non-inferiority margin). If non-inferiority is demonstrated, then a test of superiority of tenecteplase vs. alteplase will be performed as part of secondary analysis. In addition, logistic regression will be used to provide an adjusted estimate of the effectiveness of tenecteplase over alteplase for the primary outcome. The risk ratio of good 90-day outcome (mRS01) associated with the treatment groups will be estimated using a mixed-effects logistic regression model that adjusts for age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, and site, and registry (QuiCR vs. OPTIMISE) as random effects.

Secondary analyses will evaluate key safety (mortality and symptomatic intracerebral hemorrhage as defined in the AcT trial MOP) and secondary outcomes using relevant tests of association. Frequency tables will be used to summarize categorical variables by treatment group. Descriptive statistics will be used to summarize continuous data variables by treatment group.

The secondary outcomes and the corresponding analyses are described as follows. Both unadjusted (not described in Table below) and adjusted (described in table below) will be reported. Unadjusted analysis will be tests of difference in proportions, means or medians or regression analysis as appropriate. All analyses will be conducted secondary analyses are conducted at $\alpha = 0.05$.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRS 0-1 i.e., excellent functional outcome (blinded)</td>
<td>Efficacy secondary analysis of the mRS 0-1. Logistic mixed-effects regression model with treatment (Tenecteplase vs Alteplase) as exposure; age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, and site, and registry (QuiCR vs. OPTIMISE) as random effects.</td>
</tr>
<tr>
<td>mRS 0-2 i.e., good functional outcome (blinded)</td>
<td>Risk difference and the corresponding 95%CI to assess non-inferiority. Risk ratio and the 95%CI to evaluate efficacy</td>
</tr>
<tr>
<td>Supplemental material</td>
<td>Adjusted logistic mixed-effects regression model with treatment (Tenecteplase vs Alteplase) as exposure; age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, and site, and registry (QuiCR vs. OPTIMISE) as random effects.</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ordinal mRS (blinded)</td>
<td>Ordinal logistic mixed-effects regression with treatment (Tenecteplase vs Alteplase) as exposure; for age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, and site, and registry (QuiCR vs. OPTIMISE) as random effects.</td>
</tr>
</tbody>
</table>
| Return to pre-stroke status (pragmatic outcome) (blinded) | Risk difference and the corresponding 95% CI to assess non-inferiority. Risk ratio and the 95% CI to evaluate efficacy. 

Adjusted logistic regression analysis with treatment (Tenecteplase vs Alteplase) as exposure; age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, and site, and registry (QuiCR vs. OPTIMISE) as random effects. |
| Euroqol 5-D Visual Analogue Scale (EQ5D-VAS) (blinded) | A linear mixed-effects regression model with treatment (Tenecteplase vs Alteplase) as exposure; age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, and site, and registry (QuiCR vs. OPTIMISE) as random effects. |
| EQ5D-5L (blinded) | Adjusted and unadjusted ordinal logistic regression analyses will be conducted for each EQ5D item (mobility, self-care, usual activities, anxiety, and depression) as the outcome variable. 

Health utility index derived from the EQ5D-5L items. 

Linear regression analysis with robust standard errors with treatment (Tenecteplase vs Alteplase) as exposure; age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, |
<table>
<thead>
<tr>
<th>and site, and registry (QuiCR vs. OPTIMISE) as explanatory variables.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Home time</strong>*</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>In addition to home time, similar exploratory analysis will be conducted for other registry and administrative data outcomes such as length of hospital stay until discharge and discharge destination (home, home with home care, home with early supportive discharge, rehabilitation hospital, long term care and hospice) that will use appropriate regression analysis.</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Mortality</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>A Kaplan-Meier survival distribution. Patients alive after 90/120 days were censored.</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Logistic mixed-effects regression model with treatment (Tenecteplase vs Alteplase) as exposure; age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, and site, and registry (QuiCR vs. OPTIMISE) as random effects.</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Symptomatic intracerebral hemorrhage</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Logistic mixed-effects regression model with treatment (Tenecteplase vs Alteplase) as exposure; age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, and site, and registry (QuiCR vs. OPTIMISE) as random effects.</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Intracranial Hemorrhage on follow-up Imaging (Blinded)</strong></td>
</tr>
</tbody>
</table>
- Parenchymal hemorrhage (hemorrhagic infarction type 1, hemorrhagic infarction type 2, parenchymal hematoma type 1, parenchymal hematoma type 2, remote hemorrhagic infarction type 1, remote hemorrhagic infarction type 2, remote parenchymal hematoma type 1, remote parenchymal hematoma type 2)
- Subdural hemorrhage
- Subarachnoid hemorrhage
- Intraventricular hemorrhage

<table>
<thead>
<tr>
<th>Peripheral Bleeding requiring Blood Transfusion</th>
<th>Risk difference and the corresponding 95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angioedema</td>
<td>Risk difference and the corresponding 95%CI</td>
</tr>
<tr>
<td>Proportion of patients receiving EVT</td>
<td>Risk difference and the corresponding 95%CI. Logistic mixed-effects regression model with treatment (Tenecteplase vs Alteplase) as exposure; age, sex, baseline stroke severity, and stroke onset-to-needle time as fixed effects, and site, and registry (QuiCR vs. OPTIMISE) as random effects.</td>
</tr>
<tr>
<td>Other SAEs and SUSARs</td>
<td>Risk difference and the corresponding 95%CI</td>
</tr>
</tbody>
</table>
10. Subgroup Analyses
Heterogeneity in treatment effects will be explored via subgroup analyses of pre-specified prognostic variables in the ITT population primarily and in the per-protocol population secondarily. These will include analysis of primary outcome (mRS01) and key safety outcomes by
a. age (continuous and as < 80 years vs. >= 80 years),
b. sex (male vs. female),
c. baseline stroke severity as measured by the National Institute of Health Stroke Scale (NIHSS; continuous and < 8, 8-15 vs > 15),
d. presence of large vessel occlusion on baseline CTA
e. stroke onset-to-needle time (continuous and as <=180 minutes vs. > 180 minutes)
f. registry (QuiCR vs. OPTIMISE),
g. type of enrolling hospital (PSCs vs. CSCs),

Evidence of a treatment-by-sub-group variable interaction will be tested by including a multiplicative interaction term (treatment*subgroup variable) in the model. Subgroup analyses will help to determine if there is efficacy or futility in any pre-specified subgroup. Statistical significance for each subgroup analysis will be exploratory and conducted at $\alpha = 0.05$

11. Missing data
Since the trial enrolls participants using a deferred consent approach, participants with missing mRS because of refusal of consent will be excluded completely from the analysis. Under the ITT principle, all remaining patients who are randomized are included in the analysis. Thus, every effort will be made to keep all missing data to a minimum i.e., < 5%. If, despite best efforts, there are missing data, then for the primary outcome analysis, data will be assumed to be missing completely at random (MCAR). Sensitivity analyses will be conducted to examine the impact of MCAR assumption on study conclusions using available case analysis and multiple imputation methods. Similarly, assumptions and missing data methods will be adopted for analysis of secondary outcomes.
Supplement 2

eFigure 1. Participant flow diagram

eFigure 2. Comparison of hemorrhage grades as per Heidelberg Bleeding Classification between groups

eFigure 3. Kaplan-Meier curve showing time to death compared between groups.

eTable 1. Comparison of NIHSS scores between groups
eFigure 1. Participant flow diagram

1600 patients enrolled and randomly assigned to treatment

816 assigned to tenecteplase
- 10 withdrew consent
- 806 included in ITT population
  - 800 received assigned drug
  - 6 did not receive assigned drug
  - 16 excluded from per-protocol population
    - 15 had >4.5 h between stroke symptom onset and start of treatment
    - 1 received alteplase*
  - 6 lost to follow-up before 90 days

784 assigned to alteplase
- 13 withdrew consent
- 771 included in ITT population
  - 762 received assigned drug
  - 9 did not receive assigned drug
  - 11 excluded from per-protocol population
    - 11 had >4.5 h between stroke symptom onset and start of treatment
  - 4 lost to follow-up before 90 days

790 included in per-protocol analysis
760 included in per-protocol analysis

ITT=intention-to-treat. *The one patient who crossed over and received alteplase instead of tenecteplase were included in the alteplase group for safety analysis.
eFigure 2. Comparison of hemorrhage grades as per Heidelberg Bleeding Classification between alteplase and tenecteplase in minor stroke (NIHSS ≤ 5).
eFigure 3. Kaplan-Meier curve showing time to death in alteplase vs tenecteplase group.
eTable 1. Comparison of NIHSS scores between groups

<table>
<thead>
<tr>
<th>Alteplase group</th>
<th>NIHSS</th>
<th>n (%)</th>
<th>mRS 0-1, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>2</td>
<td>(1.1)</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>8</td>
<td>(4.4)</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>14</td>
<td>(7.6)</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>41</td>
<td>(22.3)</td>
<td>19</td>
</tr>
<tr>
<td>4</td>
<td>57</td>
<td>(31.0)</td>
<td>28</td>
</tr>
<tr>
<td>5</td>
<td>62</td>
<td>(33.7)</td>
<td>28</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tenecteplase group</th>
<th>NIHSS</th>
<th>n (%)</th>
<th>mRS 0-1, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>8</td>
<td>(4.1)</td>
<td>5</td>
</tr>
<tr>
<td>1</td>
<td>7</td>
<td>(3.6)</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>25</td>
<td>(12.9)</td>
<td>11</td>
</tr>
<tr>
<td>3</td>
<td>47</td>
<td>(24.2)</td>
<td>25</td>
</tr>
<tr>
<td>4</td>
<td>45</td>
<td>(23.2)</td>
<td>23</td>
</tr>
<tr>
<td>5</td>
<td>62</td>
<td>(32.0)</td>
<td>33</td>
</tr>
</tbody>
</table>